var title_f10_37_10832="Contents: Hormones";
var content_f10_37_10832=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hormones",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hormones",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adrenal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/851\">",
"           Patient information: Adrenal cancer (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Adrenal disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/26/20898\">",
"           Patient information: Addison���������s disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/19/11570\">",
"           Patient information: Adrenal crisis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/0/9220\">",
"           Patient information: Adrenal insufficiency (Addison's disease) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19330\">",
"           Patient information: Congenital adrenal hyperplasia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13619\">",
"           Patient information: Cushing's syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/61/6099\">",
"           Patient information: Cushing's syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/10994\">",
"           Patient information: Cushing's syndrome treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/27/1458\">",
"           Patient information: Pheochromocytoma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Androgen deficiency",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36562\">",
"           Patient information: Androgen replacement in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/9/18578\">",
"           Patient information: Low testosterone in men (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Breast enlargement in men",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/47/41713\">",
"           Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/30/44513\">",
"           Patient information: When men develop breasts (gynecomastia) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Contraception",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22563\">",
"           Patient information: Barrier methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9157\">",
"           Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/56/14211\">",
"           Patient information: Choosing birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12738\">",
"           Patient information: Emergency contraception (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24068\">",
"           Patient information: Emergency contraception (morning after pill) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/17/18707\">",
"           Patient information: Hormonal birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/32/22021\">",
"           Patient information: Hormonal methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/17/37138\">",
"           Patient information: Intrauterine devices (IUD) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/22/1378\">",
"           Patient information: Long-acting methods of birth control (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4355\">",
"           Patient information: Long-term methods of birth control (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7620\">",
"           Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/51/23346\">",
"           Patient information: Sterilization for women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29730\">",
"           Patient information: Vasectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/25/36242\">",
"           Patient information: Vasectomy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endometriosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/63/26611\">",
"           Patient information: Endometriosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/8/5251\">",
"           Patient information: Endometriosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Growth hormone",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17826\">",
"           Patient information: Growth hormone treatment (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Growth, puberty, and sexual health",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35973\">",
"           Patient information: Adolescent sexuality (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36562\">",
"           Patient information: Androgen replacement in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19330\">",
"           Patient information: Congenital adrenal hyperplasia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31650\">",
"           Patient information: Early puberty (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/31/13810\">",
"           Patient information: Late puberty (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23010\">",
"           Patient information: My child is overweight (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/12/3266\">",
"           Patient information: My child is short (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30738\">",
"           Patient information: Normal sexual development (puberty) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/21/1363\">",
"           Patient information: Teen sexuality (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/20/32065\">",
"           Patient information: Turner syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hirsutism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13698\">",
"           Patient information: Hirsutism (excess hair growth in women) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/56/9090\">",
"           Patient information: Hirsutism (excess hair growth in women) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infertility",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/42/22180\">",
"           Patient information: Evaluation of the infertile couple (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/62/40932\">",
"           Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/25/6547\">",
"           Patient information: Infertility in couples (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40610\">",
"           Patient information: Infertility in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/16/11523\">",
"           Patient information: Infertility in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10468\">",
"           Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/4/34883\">",
"           Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/5/32851\">",
"           Patient information: Treatment of male infertility (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Menopause",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13346\">",
"           Patient information: Atrophic vaginitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/60/23491\">",
"           Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/12/36034\">",
"           Patient information: Calcium and vitamin D for bone health (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/59/26546\">",
"           Patient information: Menopause (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/27/40370\">",
"           Patient information: Menopause (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/16/32001\">",
"           Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/49/25366\">",
"           Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32835\">",
"           Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Menstrual cycle",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22820\">",
"           Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/12/29891\">",
"           Patient information: Absent or irregular periods (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/4/36930\">",
"           Patient information: Absent or irregular periods (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/143\">",
"           Patient information: Endometrial ablation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/25/14738\">",
"           Patient information: Heavy periods (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23094\">",
"           Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/47/755\">",
"           Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11666\">",
"           Patient information: Painful periods (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/46/30437\">",
"           Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28115\">",
"           Patient information: Polycystic ovary syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13510\">",
"           Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/10/42146\">",
"           Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Metabolic syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5507\">",
"           Patient information: Metabolic syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/56/42881\">",
"           Patient information: The metabolic syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paget's disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/59/12211\">",
"           Patient information: Paget disease of bone (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/59/14258\">",
"           Patient information: Paget disease of bone (osteitis deformans) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parathyroid disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/18/6434\">",
"           Patient information: Hypoparathyroidism (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29507\">",
"           Patient information: Primary hyperparathyroidism (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/6/2147\">",
"           Patient information: Primary hyperparathyroidism (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pituitary disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/27/43443\">",
"           Patient information: Acromegaly (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40066\">",
"           Patient information: Acromegaly (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/0/25603\">",
"           Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/10/38050\">",
"           Patient information: Panhypopituitarism (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7619\">",
"           Patient information: Pituitary adenoma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/6/25698\">",
"           Patient information: Prolactinoma (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycystic ovary syndrome (PCOS)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/46/30437\">",
"           Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28115\">",
"           Patient information: Polycystic ovary syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Premature ovarian failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/63/12276\">",
"           Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/5/19538\">",
"           Patient information: Early menopause (primary ovarian insufficiency) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Premenstrual syndrome (PMS)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13510\">",
"           Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/10/42146\">",
"           Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexual problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/20/16706\">",
"           Patient information: Sex as you get older (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29205\">",
"           Patient information: Sexual problems in men (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/4/12357\">",
"           Patient information: Sexual problems in women (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sports performance enhancement",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/46/29409\">",
"           Patient information: Androgens and other hormones to boost sports performance: Risks and side effects (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/10/36002\">",
"           Patient information: Thyroid cancer (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/15/23794\">",
"           Patient information: Antithyroid drugs (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/6/3172\">",
"           Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/9/22674\">",
"           Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13219\">",
"           Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15203\">",
"           Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/54/3938\">",
"           Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/12/30914\">",
"           Patient information: Multinodular goiter (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18691\">",
"           Patient information: Thyroid nodules (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/4/23618\">",
"           Patient information: Thyroid nodules (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/42/13986\">",
"           Patient information: Thyroiditis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/50/5922\">",
"           Patient information: Thyroiditis after pregnancy (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transsexualism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/41/7826\">",
"           Patient information: Transsexualism (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urine collection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21151\">",
"           Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vaginal dryness",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13346\">",
"           Patient information: Atrophic vaginitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7537\">",
"           Patient information: Vaginal dryness (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-78B35DB936-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_37_10832=[""].join("\n");
var outline_f10_37_10832=null;
var title_f10_37_10833="Lofexidine: International drug information";
var content_f10_37_10833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lofexidine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5218643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      BritLofex (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F5218644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Lofexidine Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F5218645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F5218646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms associated with opiate (eg, methadone, heroin, hydrocodone) withdrawal such as chills, sweating, stomach cramps, muscle pain, and runny nose. Does not relieve symptoms of craving.",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F5218648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 0.8 mg/day in divided doses; titrate by 0.4-0.8 mg/day; maximum: 2.4 mg/day, should not exceed 0.8 mg/dose. Duration of treatment without concurrent opioid use: 7-10 days (longer durations may be considered).",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5218649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 0.2 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10404 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10833=[""].join("\n");
var outline_f10_37_10833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5218643\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5218644\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5218645\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5218646\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5218648\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821112\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5218649\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10404\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10404|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_37_10834="Female pelvic bones 2";
var content_f10_37_10834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Female pelvic bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Pelvis, female, anterior. Anterior view of the female pelvis.",
"    <br/>",
"    (B) Pelvis, female, posterior. Posterior view of the female pelvis.",
"    <br/>",
"    (C) Pelvis, female, superior. Superior view of the female pelvis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10834=[""].join("\n");
var outline_f10_37_10834=null;
var title_f10_37_10835="M mode mitral valve prolapse";
var content_f10_37_10835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of mitral valve prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 175px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode echocardiograms and phonocardiograms are from three patients with mitral prolapse. In all three examples the valve leaflets are thickened. In panel A, there is posterior displacement of the C-D segment that begins in early systole and persists throughout (pansystolic prolapse). In panels B and C, the prolapse begins roughly in mid-systole (late or mid-systolic prolapse). The phonocardiographic findings are not predicted by the morphologic appearance. In particular, the pansystolic prolapse in panel A has only a click (arrow) and no murmur, the example in panel B has a late systolic murmur (arrow) and no click, and the example panel C has both a click (CL) and a late systolic murmur (LSM).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10835=[""].join("\n");
var outline_f10_37_10835=null;
var title_f10_37_10836="Sapropterin: Patient drug information";
var content_f10_37_10836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sapropterin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/21/29012?source=see_link\">",
"     see \"Sapropterin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/9/31892?source=see_link\">",
"     see \"Sapropterin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5568566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kuvan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat phenylketonuria (PKU).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sapropterin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid drugs and natural products which have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695455",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       to 1 cup of water or apple juice and drink it right away. Rinse glass with more juice or water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12057 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10836=[""].join("\n");
var outline_f10_37_10836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5568566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015753\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015752\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015757\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015758\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015760\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015755\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015756\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015761\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015762\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/21/29012?source=related_link\">",
"      Sapropterin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/9/31892?source=related_link\">",
"      Sapropterin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_37_10837="Anatomy of the ischiorectal fossa";
var content_f10_37_10837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Anatomy of the ischiorectal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an illustration of the anatomy of the anus and rectum that includes the ischiorectal fossa. The left and right ischiorectal fossae communicate posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10837=[""].join("\n");
var outline_f10_37_10837=null;
var title_f10_37_10838="Neutrophil-specific granule deficiency";
var content_f10_37_10838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neutrophil-specific granule deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10838/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10838/contributors\">",
"     Robert L Roberts, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10838/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10838/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10838/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10838/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/37/10838/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophil-specific granule deficiency (SGD) is a rare congenital disorder. The cardinal clinical feature is increased susceptibility to pyogenic infections. Patients often present with large, smoldering cutaneous infections that have persisted for months (",
"    <a class=\"graphic graphic_picture graphicRef51967 \" href=\"UTD.htm?34/16/35073\">",
"     picture 1",
"    </a>",
"    ). They may also have lung abscesses and mastoiditis. The major pathogens include Staphylococcus aureus, Pseudomonas aeruginosa, other enteric gram negative bacteria, and Candida albicans.",
"   </p>",
"   <p>",
"    The diagnosis can be made by simply examining a peripheral blood smear. The neutrophils lack their specific granules and have bilobed nuclei, resembling the Pelger-Huet anomaly (",
"    <a class=\"graphic graphic_picture graphicRef71996 \" href=\"UTD.htm?8/13/8400\">",
"     picture 2",
"    </a>",
"    ). Early diagnosis of infections, antimicrobial prophylaxis, and aggressive management of infectious complications are critical. Successful hematopoietic cell transplantation was reported in one patient.",
"   </p>",
"   <p>",
"    Other congenital defects in phagocytic function are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=see_link\">",
"     \"Chediak-Higashi syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate estimate of the incidence or prevalence of SGD is difficult to obtain because the disease is so rare. Fewer than 10 cases in about five families have been reported worldwide since 1980, when the disorder was first defined [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/1\">",
"     1",
"    </a>",
"    ]. Four case reports in the 1970s of patients with recurrent pyogenic infections and neutrophil maturation defects, with absence of secondary granules and impaired neutrophil function, may also have been cases of SGD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The disease occurs in both males and females.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactoferrin is absent in neutrophils of patients with SGD, but normal levels of lactoferrin are secreted by nasal epithelial cells in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Levels of RNA for neutrophil specific granule products, including lactoferrin, transcobalamin F, neutrophil collagenase, neutrophil gelatinase, and defensins, are greatly reduced in SGD bone marrow, compared to normal bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The findings above suggested a defect in a myeloid-specific transcription factor. This defect was identified in",
"    <span class=\"nowrap\">",
"     CCAAT/enhancer",
"    </span>",
"    binding protein epsilon",
"    <span class=\"nowrap\">",
"     (C/EBP-epsilon),",
"    </span>",
"    a transcription factor expressed primarily in myeloid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    knockout mice were first noted to have neutrophil abnormalities and susceptibility to bacterial infections similar to patients with SGD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/10\">",
"     10",
"    </a>",
"    ]. This prompted the sequencing of the",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    locus in a patient with SGD. A five-base pair deletion in the second exon of",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    was identified in this patient. The frame shift resulted in a truncated protein that no longer had a DNA binding region or transcriptional activity. Mutations in the",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    gene were identified in several additional patients with SGD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. All patients have been homozygous for the mutated gene, with heterozygous parents. Thus, this disorder appears to have autosomal recessive inheritance.",
"   </p>",
"   <p>",
"    Of note, mutations in",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    have not been identified in all known patients with SGD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/14\">",
"     14",
"    </a>",
"    ]. One patient with SGD was identified who had a heterozygous mutation in the",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    gene, but had elevated levels of",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/13\">",
"     13",
"    </a>",
"    ]. Growth factor independence 1 (Gfi-1) was low in this patient, although a mutation in the gene for this transcription factor was not found. Gfi-1 represses transcription of",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon.",
"    </span>",
"    In a mouse model, reduced levels of Gfi-1 are associated with decreased levels of specific granule",
"    <span class=\"nowrap\">",
"     proteins.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;C/EBP-epsilon",
"    is expressed exclusively in myeloid and T cells. The defect in",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    appears to block the transition of neutrophils from the promyelocyte to myelocyte stage (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ), so the cells are released in an abnormal state [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/9\">",
"     9",
"    </a>",
"    ]. Primary or azurophilic granule proteins are produced in myeloblasts and promyelocytes, whereas secondary or specific granule proteins are synthesized in myelocytes and metamyelocytes and tertiary or gelatinase granule proteins are generated in bands and polymorphonuclear neutrophils (PMNs) (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"UTD.htm?41/7/42109\">",
"     table 1",
"    </a>",
"    ). Thus, both specific and gelatinase granules are absent in patients with SGD and abnormalities are seen in azurophilic granules as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lactoferrin deficiency and absence of specific granules were the first defects noted in patients with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. Lactoferrin, which is the primary enzyme in specific granules, has strong bacteriostatic properties. Specific granules play an important role in neutrophil locomotion and oxidative metabolism. These granules contain various receptors as well as enzymes. Chemotactic receptors in specific granules translocate to the cell membrane when activated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/16\">",
"     16",
"    </a>",
"    ]. Neutrophils from a patient with SGD showed a reduced chemotactic response to several stimuli and decreased neutrophil and monocyte mobilization in response to skin abrasion (Rebuck skin window technique) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/15\">",
"     15",
"    </a>",
"    ]. Neutrophils also had decreased oxidative responses.",
"   </p>",
"   <p>",
"    It was later found that neutrophils from patients with SGD are also deficient in defensins,",
"    <span class=\"nowrap\">",
"     microbicidal/cytotoxic",
"    </span>",
"    proteins present in azurophilic granules [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/17\">",
"     17",
"    </a>",
"    ]. This defect also occurs in Chediak-Higashi neutrophils, and it contributes to the tendency to develop severe pyogenic infections in both diseases. The almost complete absence of defensins is due to a reduced level of defensins per granule rather than a decrease in the number of azurophilic or primary granules [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, both specific and azurophilic granules are affected in SGD.",
"   </p>",
"   <p>",
"    Eosinophil granules are also affected in this disease. Eosinophils in patients with SGD cannot be distinguished from neutrophils by light microscopy because both are granule-deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/19\">",
"     19",
"    </a>",
"    ]. These eosinophils contain eosinophil peroxidase (EPO) and Charcot-Leyden crystal protein and proliferate when exposed to granulocyte-macrophage colony stimulating factor (GM-CSF), as do normal eosinophils. However, these cells lack eosinophil-specific granule proteins, including eosinophilic cationic protein, eosinophil-derived neurotoxin, and major basic protein.",
"   </p>",
"   <p>",
"    Abnormalities in monocytes are also seen with this disease. Monocytes (CD14+ cells) from a patient with SGD were found to have decreased levels of the monocyte-specific enzyme, nonspecific esterase, and electron-microscopic examination revealed morphologic differences between SGD monocytes and normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/20\">",
"     20",
"    </a>",
"    ]. IL-6 modulates acute phase reactants and enhances B cell antibody production, and IL-8 is chemoattractant involved in cellular migration into tissues during an inflammatory response. IL-6 levels were lower and IL-8 levels higher during sepsis in patients with SGD compared with normal controls. Macrophages in",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    knockout mice had decreased chemotaxis and cytokine production, as well as reduced capacity to accumulate lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet disorders with associated bleeding diatheses are also reported. One patient who had increased bleeding following surgical procedures lacked intermediate and high molecular weight von Willebrand factor (vWf) multimers and had no poststimulation increase of vWf surface expression on platelets due to decreased binding [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/22\">",
"     22",
"    </a>",
"    ]. Platelet fibrinogen and fibronectin were also reduced in this patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of presentation of SGD is in the first few years of life. The cardinal clinical feature is increased susceptibility to pyogenic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/1,2,15,23\">",
"     1,2,15,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with SGD usually present with severe, chronic cutaneous infections, often with ulcers and abscesses (",
"    <a class=\"graphic graphic_picture graphicRef51967 \" href=\"UTD.htm?34/16/35073\">",
"     picture 1",
"    </a>",
"    ). Chronic and recurrent lung infections, including pneumonia and abscesses are also common. Patients may also develop septicemia and recurrent mastoiditis, otitis media, and lymphadenitis with draining lymph nodes. One infant presented with vomiting, intractable watery diarrhea, and failure to thrive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent pulmonary infections can lead to chronic lung disease. The patient may be clinically stable if infections are controlled and there is no permanent damage to the lungs or another vital organ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathognomonic laboratory findings in neutrophils on a peripheral smear are paucity or absence of specific granules and predominantly bilobed nuclei (pseudo Pelger-Huet anomaly) (",
"    <a class=\"graphic graphic_picture graphicRef71996 \" href=\"UTD.htm?8/13/8400\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/1\">",
"     1",
"    </a>",
"    ]. Eosinophils may be mononuclear and are not easily distinguished from other \"granulocytes\" by light microscopy because they also lack their characteristic granules [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophils have abnormal chemotaxis (locomotion), normal aggregation but impaired disaggregation, decrease bactericidal activity, and abnormal superoxide release [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major pathogens are Staphylococcus aureus, Pseudomonas aeruginosa, and other enteric gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Fungal infections with Candida albicans may also occur.",
"   </p>",
"   <p>",
"    Bleeding time may be prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/22\">",
"     22",
"    </a>",
"    ]. Thrombocytopenia may occur during infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made by examining a peripheral smear (",
"    <a class=\"graphic graphic_picture graphicRef71996 \" href=\"UTD.htm?8/13/8400\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/1,6,25,26\">",
"     1,6,25,26",
"    </a>",
"    ]. All the \"granulocytes\" will lack specific granules, making it difficult to distinguish neutrophils and eosinophils. Most of the neutrophils will have bilobed nuclei. Histochemical analysis of the neutrophils will reveal deficiency of lactoferrin, B-12 binding protein, and defensins. Most patients have mutations in the",
"    <span class=\"nowrap\">",
"     C/EBP-epsilon",
"    </span>",
"    gene (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetics'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are often more severe than suggested by the clinical examination, because of defective inflammatory responses. Early diagnosis of infections, antimicrobial prophylaxis, and aggressive management of infectious complications are critical management components. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic granulomatous disease: Treatment and prognosis\", section on 'Acute infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists mainly of intensive intravenous antibiotics for active infections. Prophylactic antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , are recommended to prevent infection, based upon data from other primary phagocytic disorders. Growth factors such as granulocyte-colony stimulating factor might be considered. Surgical excision and debridement of the larger cutaneous and soft tissue abscesses are often required.",
"   </p>",
"   <p>",
"    One patient underwent hematopoietic cell transplantation (HCT) at 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10838/abstract/24\">",
"     24",
"    </a>",
"    ]. The patient received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    conditioning prior to HCT. Her course was complicated by Candida infection, GVHD, and mild venoocclusive disease. At 1.5 years after HCT, she was well and had full donor cell engraftment. Her gastrointestinal symptoms (vomiting and intractable diarrhea) and recurrent infections have disappeared. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis is difficult to predict, given the rarity of the disease. However, some patients with SGD have survived into adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutrophil-specific granule deficiency (SGD) is a rare congenital disorder characterized by increased susceptibility to pyogenic infections, especially of the skin, lungs, ears, and lymph nodes. The major pathogens include Staphylococcus aureus, Pseudomonas aeruginosa, other enteric gram negative bacteria, and Candida albicans. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SGD appears to be an autosomal recessive disorder. At least one defective gene has been identified, the",
"      <span class=\"nowrap\">",
"       CCAAT/enhancer",
"      </span>",
"      binding protein epsilon",
"      <span class=\"nowrap\">",
"       (C/EBP-epsilon)",
"      </span>",
"      gene. Specific granules are significantly decreased to absent in neutrophils and eosinophils. Function of neutrophils, eosinophils, monocytes, and platelets is impaired. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made by examining neutrophils in a peripheral blood smear for the pathognomonic laboratory findings of paucity or absence of specific granules and predominantly bilobed nuclei (pseudo Pelger-Huet anomaly). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early diagnosis of infections, antimicrobial prophylaxis, and aggressive management of infectious complications are critical management components. We suggest an approach similar to that taken with chronic granulomatous disease, except for the use of interferon-gamma. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=see_link&amp;anchor=H7#H7\">",
"       \"Chronic granulomatous disease: Treatment and prognosis\", section on 'Acute infections'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/1\">",
"      Breton-Gorius J, Mason DY, Buriot D, et al. Lactoferrin deficiency as a consequence of a lack of specific granules in neutrophils from a patient with recurrent infections. Detection by immunoperoxidase staining for lactoferrin and cytochemical electron microscopy. Am J Pathol 1980; 99:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/2\">",
"      Komiyama A, Morosawa H, Nakahata T, et al. Abnormal neutrophil maturation in a neutrophil defect with morphologic abnormality and impaired function. J Pediatr 1979; 94:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/3\">",
"      Spitznagel JK, Cooper MR, McCall AE, et al. Selective deficiency of granules associated with lysozyme and lactoferrin in human polymorphs with reduced microbicidal capacity. J Clin Invest 1972; 51:93a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/4\">",
"      Strauss RG, Bove KE, Jones JF, et al. An anomaly of neutrophil morphology with impaired function. N Engl J Med 1974; 290:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/5\">",
"      Parmley RT, Ogawa M, Darby CP Jr, Spicer SS. Congenital neutropenia: neutrophil proliferation with abnormal maturation. Blood 1975; 46:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/6\">",
"      Lomax KJ, Gallin JI, Rotrosen D, et al. Selective defect in myeloid cell lactoferrin gene expression in neutrophil specific granule deficiency. J Clin Invest 1989; 83:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/7\">",
"      Raphael GD, Davis JL, Fox PC, et al. Glandular secretion of lactoferrin in a patient with neutrophil lactoferrin deficiency. J Allergy Clin Immunol 1989; 84:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/8\">",
"      Johnston JJ, Boxer LA, Berliner N. Correlation of messenger RNA levels with protein defects in specific granule deficiency. Blood 1992; 80:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/9\">",
"      Lekstrom-Himes JA, Dorman SE, Kopar P, et al. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. J Exp Med 1999; 189:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/10\">",
"      Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A 1997; 94:13187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/11\">",
"      Gombart AF, Shiohara M, Kwok SH, et al. Neutrophil-specific granule deficiency: homozygous recessive inheritance of a frameshift mutation in the gene encoding transcription factor CCAAT/enhancer binding protein--epsilon. Blood 2001; 97:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/12\">",
"      Khanna-Gupta A, Zibello T, Sun H, et al. C/EBP epsilon mediates myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut). Proc Natl Acad Sci U S A 2001; 98:8000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/13\">",
"      Khanna-Gupta A, Sun H, Zibello T, et al. Growth factor independence-1 (Gfi-1) plays a role in mediating specific granule deficiency (SGD) in a patient lacking a gene-inactivating mutation in the C/EBPepsilon gene. Blood 2007; 109:4181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/14\">",
"      Gombart AF, Koeffler HP. Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon). Curr Opin Hematol 2002; 9:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/15\">",
"      Gallin JI, Fletcher MP, Seligmann BE, et al. Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Blood 1982; 59:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/16\">",
"      Gallin JI. Neutrophil specific granule deficiency. Annu Rev Med 1985; 36:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/17\">",
"      Ganz T, Metcalf JA, Gallin JI, et al. Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and \"specific\" granule deficiency. J Clin Invest 1988; 82:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/18\">",
"      Parmley RT, Gilbert CS, Boxer LA. Abnormal peroxidase-positive granules in \"specific granule\" deficiency. Blood 1989; 73:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/19\">",
"      Rosenberg HF, Gallin JI. Neutrophil-specific granule deficiency includes eosinophils. Blood 1993; 82:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/20\">",
"      Shiohara M, Gombart AF, Sekiguchi Y, et al. Phenotypic and functional alterations of peripheral blood monocytes in neutrophil-specific granule deficiency. J Leukoc Biol 2004; 75:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/21\">",
"      Gombart AF, Krug U, O'Kelly J, et al. Aberrant expression of neutrophil and macrophage-related genes in a murine model for human neutrophil-specific granule deficiency. J Leukoc Biol 2005; 78:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/22\">",
"      Parker RI, McKeown LP, Gallin JI, Gralnick HR. Absence of the largest platelet-von Willebrand multimers in a patient with lactoferrin deficiency and a bleeding tendency. Thromb Haemost 1992; 67:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/23\">",
"      Ambruso DR, Sasada M, Nishiyama H, et al. Defective bactericidal activity and absence of specific granules in neutrophils from a patient with recurrent bacterial infections. J Clin Immunol 1984; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/24\">",
"      Wynn RF, Sood M, Theilgaard-M&ouml;nch K, et al. Intractable diarrhoea of infancy caused by neutrophil specific granule deficiency and cured by stem cell transplantation. Gut 2006; 55:292.",
"     </a>",
"    </li>",
"    <li>",
"     Stiehm ER, Ochs HD, Winkelstein JA. Phagocyte disorders. In: Immunologic disorders in infants and children, 5th ed, Saunders, London 2004. p.640.",
"    </li>",
"    <li>",
"     Nathan DG, Ginsburg D, Orkin SH, Look TA. The phagocyte system and disorders of granulopoiesis and granulocyte function. In: Hematology of infancy and childhood, Saunders, London  p.923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10838/abstract/27\">",
"      Sakura T, Murakami H, Matsushima T, et al. Ultrastructure of neutrophilic phagosome of autologous platelet in vivo in specific granule deficiency. Am J Hematol 1993; 43:149.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3933 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10838=[""].join("\n");
var outline_f10_37_10838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3933|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/58/31651\" title=\"figure 1\">",
"      PMN development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3933|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/16/35073\" title=\"picture 1\">",
"      Patient with SGD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/13/8400\" title=\"picture 2\">",
"      SGD neutrophil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/7/42109\" title=\"table 1\">",
"      PMN granule contents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11465?source=related_link\">",
"      Chronic granulomatous disease: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_37_10839="Lymphangitic cancer CT I";
var content_f10_37_10839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69355%7EPULM%2F79160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69355%7EPULM%2F79160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography appearance of lymphangitic carcinomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphangitic carcinomatosis from metastatic carcinoma of the cervix characterized by diffuse bilateral thickening of bronchovascular bundles. Peribronchial thickening results in visualization of more peripheral bronchi. The major fissures are slightly thickened. Several thickened interlobular septa are seen in the posterior aspect of the right lung. Small subpleural nodules represent thickened centrilobular bronchovascular structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT appearance of asymmetric lymphangitic carcinomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Asymmetric lymphangitic spread of bronchogenic carcinoma, primarily involving the right lung. Thickened bronchovascular bundles and a fine reticular pattern are seen and probably represent thickened interlobular and intralobular septae. Polygon formation is seen in the anterior and medial aspect of the right lung. Several thickened interlobular septa are present, abutting the medial pleura of the right lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10839=[""].join("\n");
var outline_f10_37_10839=null;
var title_f10_37_10840="Amanita smithiana and Tricholoma magnivelare mushroom";
var content_f10_37_10840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Amanita smithiana and Tricholoma magnivelare (Matsutake or pine) mushroom",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Amanita smithiana mushrooms cause acute gastroenteritis and delayed renal failure due to the action of the toxin allenic norleucine and may be mistaken for Tricholoma magnivelare (Matsutake or pine mushroom). Their appearance is similar to the amatoxin-containing Amanita genus mushrooms such as Amanita phalloides, A. verna, A. virosa, and A. bisporigea.",
"    <br>",
"     (B) Tricholoma magnivelare (Matsutake or pine mushroom) is a prized gourmet mushroom.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Patrick West, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10840=[""].join("\n");
var outline_f10_37_10840=null;
var title_f10_37_10841="Overview of craniosynostosis";
var content_f10_37_10841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of craniosynostosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Edward P Buchanan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Patrick Cole, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Larry H Hollier, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10841/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/37/10841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interruption of normal embryologic craniofacial differentiation can produce a wide variety of craniofacial abnormalities. Many of the more profound craniofacial deformities occur secondary to craniosynostosis or premature fusion of one or more cranial sutures. Reconstruction of craniofacial structure is typically required when physical or mental well-being becomes affected.",
"   </p>",
"   <p>",
"    The pathogenesis, diagnosis, and surgical management of craniosynostosis are reviewed here. Specific syndromes associated with craniofacial abnormalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link\">",
"     \"Syndromes with craniofacial abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRANIAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn infant's skull is composed of bony plates separated by sutures. This arrangement accommodates transient skull distortion during birth and permits future growth of the brain, the volume of which quadruples during the first two years of life. There are four major sutures: the metopic, coronal, sagittal, and lambdoid. Three additional sutures that contribute to calvarial development are considered minor: the frontonasal, temporosquamosal, and frontosphenoidal. The sagittal, coronal, and metopic sutures meet at the anterior of the skull to form the anterior fontanelle, palpable just behind the forehead at the midline. The posterior fontanelle is formed by the intersection of the sagittal and lambdoid sutures (",
"    <a class=\"graphic graphic_figure graphicRef81518 \" href=\"UTD.htm?16/32/16898\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The osseous cranial base is embryologically derived from a cartilaginous framework (endochondral bone) that undergoes a proliferative growth pattern. In contrast, the calvarium consists of membranous bone, which has no cartilaginous phase. The calvarium grows by depositing new bone along suture lines in response to the distending forces of the rapidly growing brain. During the first two years after birth, the brain increases in size to 75 percent of its adult volume (",
"    <a class=\"graphic graphic_figure graphicRef64098 \" href=\"UTD.htm?1/51/1854\">",
"     figure 2",
"    </a>",
"    ). The remaining 25 percent of growth occurs during the next 18 years.",
"   </p>",
"   <p>",
"    Fontanelle and suture closure occurs in a specific pattern (",
"    <a class=\"graphic graphic_table graphicRef57361 \" href=\"UTD.htm?1/23/1403\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70196 \" href=\"UTD.htm?6/15/6395\">",
"     table 2",
"    </a>",
"    ). At two months of age, the posterior fontanelle closes, followed by anterior fontanelle closure at approximately two years. The anterolateral and posterolateral fontanelles close at three months and one year, respectively. While the metopic suture typically closes at two years of age, all remaining patent sutures close in adulthood following completion of craniofacial growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniosynostosis results from premature fusion of one or more cranial sutures (",
"    <a class=\"graphic graphic_table graphicRef70196 \" href=\"UTD.htm?6/15/6395\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81518 \" href=\"UTD.htm?16/32/16898\">",
"     figure 1",
"    </a>",
"    ), and affects 1 in every 2000 to 2500 births worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/1\">",
"     1",
"    </a>",
"    ]. Premature fusion restricts the growth of the skull perpendicular to the affected suture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/2\">",
"     2",
"    </a>",
"    ]. In order to accommodate the growing brain, compensatory skull growth occurs parallel to the affected suture. The resulting skull deformity is dependent upon which suture(s)",
"    <span class=\"nowrap\">",
"     is/are",
"    </span>",
"    affected (",
"    <a class=\"graphic graphic_figure graphicRef52793 \" href=\"UTD.htm?38/49/39699\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Craniosynostosis may involve any of the sutures in isolation or multiple sutures, although the sagittal suture is affected most often. In a review of 519 subjects, the sagittal suture was affected in 56 percent, the coronal suture in 25 percent, the metopic suture in 4 percent, and the lambdoid suture in 2 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/3\">",
"     3",
"    </a>",
"    ]. Multiple sutures were affected in only 13 percent of cases. In general, craniosynostosis involving a single suture occurs sporadically and as an isolated defect. There is an increased incidence of craniosynostosis in multiple pregnancies and in the presence of uterine abnormalities such as bicornuate uterus implying that compression of the fetal skull during pregnancy can contribute to craniosynostosis. In contrast, craniosynostosis involving multiple sutures is often part of a genetic syndrome with additional anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several additional hypotheses regarding the mechanisms underlying premature closure of cranial sutures in nonsyndromic have been proposed. According to Moss's dural hypothesis, abnormal dural attachments exert restrictive tensile forces that arrest bone growth and lead to premature suture closure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/5\">",
"     5",
"    </a>",
"    ]. An alternative theory is that an intrinsic abnormality in the cranial base produces early fusion. This theory is supported by data from laboratory studies of osteoblasts retrieved from craniosynostotic tissues. In culture, these cells demonstrate prolonged doubling time and are inhibited by exposure to osteoblast growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, craniosynostosis is associated with endocrine abnormalities, such as hyperthyroidism, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    use during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in specific genes have been identified in most of the common autosomal dominant craniosynostosis syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/9\">",
"     9",
"    </a>",
"    ]. Most mutations affect genes that code for members of the fibroblast growth factor receptor family (FGFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/10\">",
"     10",
"    </a>",
"    ]. Mutations in these genes are also found in patients with nonsyndromic craniosynostosis. In a study of 57 patients with bilateral coronal synostosis, mutations in FGFR2 or FGFR3 were identified in all patients with a phenotypic diagnosis (Apert, Crouzon, or Pfeiffer syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/11\">",
"     11",
"    </a>",
"    ]. Mutations in these genes also were found in 14 of 19 patients who could not be classified clinically. In another series, the most commonly mutated genes were FGFR2, FGFR3, TWIST1 (encodes the transcription factor twist homologue 1), and EFNB1 (encodes ephrin-B1, a protein involved in cell recognition) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/12\">",
"     12",
"    </a>",
"    ]. Single gene disorders accounted for 86 percent of the molecular defects identified in this study, whereas chromosome abnormalities occurred in only 14 percent (one patient had both). Syndromic craniosynostosis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CATEGORIZATION OF CRANIAL DEFORMITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cranial deformation is categorized as scaphocephaly, plagiocephaly, trigonocephaly, kleeblattsch&auml;del, or acrocephaly, depending upon which suture(s)",
"    <span class=\"nowrap\">",
"     is/are",
"    </span>",
"    involved (",
"    <a class=\"graphic graphic_figure graphicRef52793 \" href=\"UTD.htm?38/49/39699\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Scaphocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scaphocephaly (dolichocephaly), also known as hull-shaped skull, is caused by premature fusion of the sagittal suture, which results in decreased width and inverse elongation of the anteroposterior axis of the cranium (",
"    <a class=\"graphic graphic_picture graphicRef54482 \" href=\"UTD.htm?36/51/37683\">",
"     picture 1",
"    </a>",
"    ). Scaphocephaly accounts for approximately 50 percent of craniosynostosis cases, occurring with an estimated incidence of 1 in 2000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Plagiocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plagiocephaly, or twisted skull, is the result of unilateral coronal or lambdoidal synostosis.",
"   </p>",
"   <p>",
"    Premature closure of a unilateral coronal suture, anterior plagiocephaly, occurs in 1 in 10,000 live births. Anterior plagiocephaly is characterized by flattening of the forehead and elevation of the eyebrow on the affected side. The contralateral forehead becomes excessively prominent as a result of compensatory overgrowth, and the ear on the affected side is displaced anteriorly and superiorly. The chin and nose deviate to the unaffected side. In anteroposterior (AP) radiographs of the face, the affected orbit has a Mardi Gras-mask-like appearance referred to as harlequin eye deformity.",
"   </p>",
"   <p>",
"    Premature closure of a unilateral lambdoid suture results in ipsilateral occipitoparietal flattening, or posterior plagiocephaly (",
"    <a class=\"graphic graphic_figure graphicRef60493 \" href=\"UTD.htm?29/63/30719\">",
"     figure 4",
"    </a>",
"    ). The forehead on the contralateral side bulges forward, while the forehead on the ipsilateral side is set back. The ear is low set on the affected side. Ear placement is anterior, symmetric, or posterior in relation to the contralateral ear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Trigonocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigonocephaly is caused by premature closure of the metopic suture and accounts for approximately 10 percent of craniosynostosis cases. Trigonocephaly is characterized by a narrow, triangle-shaped forehead with a prominent midline ridge, resembling a keel, and superior-lateral orbital depression, and hypotelorism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Affected patients also have compensatory occipital-parietal calvarial changes, such as recessed lateral orbits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Kleeblattsch&auml;del",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kleeblattsch&auml;del, also known as cloverleaf deformity, occurs when multiple sutures fuse prematurely. The coronal, lambdoid, and metopic sutures are most frequently affected. Bulging of the skull through the open sagittal and temporosquamosal sutures produces a trilobate skull. Kleeblattsch&auml;del is a rare anomaly, with fewer than 130 cases reported in the literature. Kleeblattsch&auml;del is the most severe form of cranial dysostoses; nearly all affected patients have hydrocephalus and intellectual disability (mental retardation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acrocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acrocephaly, also known as tower skull, results from combined sagittal, coronal, and lambdoid synostosis. The anterior cranium is elevated relative to the posterior cranium, causing the vault to slant from front to back. Acrocephaly is often seen in Crouzon or Apert syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other deformities",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brachycephaly results from bilateral coronal synostosis. The cranium is shortened in length and increased in both width and height.",
"     </li>",
"     <li>",
"      Oxycephaly or turricephaly refers to a tall cranium with diminished growth in the anteroposterior and lateral dimensions; the nasofrontal angle is obtuse or blunted. Oxycephaly may occur when treatment of bicoronal synostosis is delayed or inadequate. In other words, it may be a natural progression of brachycephaly if bicoronal synostosis is untreated. This presentation is often found in syndromic craniosynostosis, and may be associated with abnormalities in sutures other than the coronal sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The categorization of craniofacial deformities is often based upon clinical appearance or embryogenesis of the involved craniofacial structure. Craniofacial anomalies are typically divided into two large subgroups: craniosynostosis and clefting. The craniosynostosis subgroup can be further divided into isolated and syndromic. To date no single, wholly effective classification system for craniosynostosis exists [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Continued improvements in the understanding of these defects should lead to a future system that comprehensively categorizes each type of synostosis according to underlying cause [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link\">",
"     \"Syndromes with craniofacial abnormalities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44581?source=see_link\">",
"     \"Facial clefts and holoprosencephaly\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=see_link\">",
"     \"Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of craniofacial deformity is primarily based upon physical examination. Radiographic studies, such as plain radiographs and computed tomography (CT), may further characterize the structural abnormality. However, making a specific diagnosis can be complicated when features overlap two known syndromes or otherwise fail to fit into a defined clinical category [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/18\">",
"     18",
"    </a>",
"    ]. Radiographic studies are best performed at a center with a craniofacial team. On occasion, molecular diagnosis is available (eg, Apert or Crouzon syndrome). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Categorization of cranial deformities'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) can identify the sutures more accurately than can plain radiographs and can be used to assess the extent of fusion and its effect on adjacent bones. The brain can be examined for abnormalities, including hydrocephalus. Asymmetry and deformities of the cranial base can be seen. CT also is used to evaluate the spatial and geometric relationships between the bony orbit and its soft tissue contents (the globe and extraocular muscles) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three-dimensional surface reconstructions using CT can assist in the classification of craniofacial disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/21\">",
"     21",
"    </a>",
"    ]. These images, together with cephalometric and anthropometric data, can be used to quantitate the skeletal deformity and plan surgical treatment of complex craniofacial reconstructions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in intracranial volume can be calculated in children with craniosynostosis using CT, although these measurements typically are within normal limits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cephalometrics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalometry is the precise measurement of the dimensions of the head. Cephalometric radiography is a standardized technique that enables accurate longitudinal studies of head growth. Standardization is achieved by a constant orientation of the X-ray axis, the patient's head, and the film. The orienting device, called a cephalometer, stabilizes the patient's head with a pair of ear rods that enter the external auditory meatus, and a third rod, which rests on the nasofrontal suture, thereby preventing sagittal rotation of the head. The radiographic film is held at a constant distance from the midline of the head and the X-ray source. Lateral and frontal views are obtained. Skeletal landmarks are identified in order to compare lengths and angles to normal values or in the same patient over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early screening for mutations that affect genes encoding for members of the fibroblast growth factor receptor family (FGFR) can be performed in affected newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/27\">",
"     27",
"    </a>",
"    ]. Causative mutations are more commonly identified in children with unicoronal or bicoronal, rather than sagittal or metopic, nonsyndromic craniosynostosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link\">",
"     \"Craniosynostosis syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF FACIAL ASYMMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions can result in facial asymmetry and must be differentiated from craniosynostosis. They include positional deformities and congenital muscular torticollis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Positional flattening (positional plagiocephaly)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior synostotic plagiocephaly (",
"    <a class=\"graphic graphic_figure graphicRef60493 \" href=\"UTD.htm?29/63/30719\">",
"     figure 4",
"    </a>",
"    ) may be confused with positional skull flattening (also called positional plagiocephaly) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/28\">",
"     28",
"    </a>",
"    ]. The frequency of the latter condition has increased, in part because of supine sleep positioning to prevent sudden infant death syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In a prospective cohort study of 200 infants, the prevalence of nonsynostotic plagiocephaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brachycephaly at 6 weeks and at 4, 8, 12, and 24 months was 16, 20, 9, 7, and 3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/30\">",
"     30",
"    </a>",
"    ]. Risk factors for nonsyndromic plagiocephaly included limited head rotation, supine sleep position, and decreased activity levels. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Congenital torticollis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link&amp;anchor=H9951026#H9951026\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Other measures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The position of the ear is the most reliable indicator of the correct diagnosis, but CT studies have shown that ear position is not completely reliable in this matter [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The ear is displaced away (anteriorly) from the flattened region in posterior positional plagiocephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/31\">",
"     31",
"    </a>",
"    ]. In contrast, the ear placement may be symmetric in posterior synostotic plagiocephaly, displaced away from the affected side (anteriorly) or displaced toward the affected side (posteriorly) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/32\">",
"     32",
"    </a>",
"    ]. As expected, anterior positional plagiocephaly is very uncommon, since children rarely experience prolonged pressure to the anterior aspects of the head. If the diagnosis of positional plagiocephaly is uncertain, a plain radiograph of the skull may be obtained to confirm that the sutures are patent. In most cases, positional plagiocephaly can be treated without surgery by change in positioning [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/34\">",
"     34",
"    </a>",
"    ]. In severe cases (which are rare), a custom-fitted helmet designed to relieve pressure on the flattened side can be applied [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/31,35,36\">",
"     31,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Localized lateral or occipital cranial flattening at birth is common and may be a precursor to posterior deformational plagiocephaly. In one study of healthy newborns, localized cranial flattening and other unusual head shapes (eg, dolichocephalous or protruding occiput) occurred in 13 and 11 percent, respectively, of singletons [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/37\">",
"     37",
"    </a>",
"    ]. Localized flattening was more common in twins, occurring in 56 percent. Findings shared by localized flattening at birth and posterior deformational plagiocephaly that becomes apparent at two to three months of age suggested that the former may lead to the latter. These included boys affected more than girls, right side affected more than left, twins affected more than singletons, increased incidence of other deformations (eg, club feet) and cephalohematoma, primiparity, long labor, and assisted delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Congenital torticollis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital torticollis may result in anterior positional plagiocephaly. Affected infants maintain their external ear close to the shoulder on one side with the face turned to the other side, which may lead to positional deformation of the skull. In one review, all infants who presented with torticollis had craniofacial asymmetry, which typically was not striking [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/38\">",
"     38",
"    </a>",
"    ]. Affected patients had anterior plagiocephaly consisting of recession of the ipsilateral zygoma and forehead and reduction of the vertical facial height on the affected side. Treatment of the torticollis alone was sufficient in most cases, although surgical intervention was needed to correct the skull deformity in severely affected children who presented later in childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=see_link\">",
"     \"Congenital muscular torticollis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1378999\">",
"    <span class=\"h2\">",
"     Other causes of facial asymmetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of facial asymmetry include Parry-Romberg Disease, craniofacial microsomia, and congenital facial paralysis. Unilateral tumors, such as juvenile hemangioma, neurofibromatosis, fibrous dysplasia, lymphangioma, osteoma, embryonal rhabdomyosarcoma, and Burkitt's lymphoma, can result in abnormal craniofacial appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377304\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with craniosynostosis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intracranial pressure (ICP) and inhibition of brain growth. Brain growth is inhibited by prolonged uncorrected restriction of cranial growth. Compression of the underlying brain is more likely when multiple sutures are affected.",
"     </li>",
"     <li>",
"      Associated impairments in cognitive and neurodevelopment function, including global developmental delay, poor feeding and weight gain, and deficits in vision, hearing, and speech.",
"     </li>",
"     <li>",
"      Poor self-esteem and social isolation due to the abnormal appearance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377311\">",
"    <span class=\"h2\">",
"     Increased ICP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased ICP occurs more frequently in untreated craniosynostosis involving multiple sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/40\">",
"     40",
"    </a>",
"    ]. Acquired Chiari malformations that often require decompression are also more common in children with nonsyndromic, multisutural craniosynostosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of 1727 cases of craniosynostosis, cerebrospinal fluid (CSF) hydrodynamics were abnormal in 8 percent, and approximately 4 percent required shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/3\">",
"     3",
"    </a>",
"    ]. Subsequent smaller-scale studies showed elevated intracranial pressure in 15 to 20 percent of children with isolated single-suture craniosynostosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Abnormalities in CSF hydrodynamics included progressive hydrocephalus with ventricular dilation, nonprogressive ventriculomegaly, and dilation of the subarachnoid spaces. Importantly, elevated ICP does not correlate well with cranial volume as measured by computed tomography (CT) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hydrocephalus occurred in all patients with kleeblattsch&auml;del [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/3\">",
"     3",
"    </a>",
"    ]. It was more frequent in patients with syndromic than isolated craniosynostosis (12 versus 0.3 percent) and in Crouzon syndrome than in other syndromes. Ventricular dilation occurred frequently in Apert syndrome, but typically was nonprogressive. Venous sinus obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic tonsillar herniation were evident in most cases of syndromic craniosynostosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1377318\">",
"    <span class=\"h2\">",
"     Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with nonsyndromic craniosynostosis demonstrate an increased incidence of speech-language, cognitive, behavioral, and neurodevelopmental abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/41,46-49\">",
"     41,46-49",
"    </a>",
"    ]. The exact relationship between structural and developmental abnormalities remains unclear. To date, the relationship between surgical correction of craniosynostosis and changes in neurodevelopment remains equally nebulous [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/48,50\">",
"     48,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, 15 children &lt;1 year of age with single-suture, nonsyndromic craniosynostosis were evaluated by the Bayley Scales of Infant Development two months before and one year after surgical correction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/51\">",
"     51",
"    </a>",
"    ]. The mean score for mental development index was unchanged before and after surgery (82 versus 79); however, there was improvement in psychomotor development indices (79 versus 89). In contrast, a literature review of 17 studies concluded that there was little evidence that surgery affects the risk of neurodevelopmental impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal care of patients with craniofacial anomalies requires a multidisciplinary approach. This approach has been supported by a consensus conference of the American Cleft Palate-Craniofacial Association [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/52\">",
"     52",
"    </a>",
"    ]. The recommendations emphasize management by an interdisciplinary team [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/53\">",
"     53",
"    </a>",
"    ]. The team consists of specialists from anesthesiology, audiology, cardiology, dermatology, radiology, genetic counseling, medical genetics, neurology, neurosurgery, nursing, ophthalmology, oral and maxillofacial surgery, microsurgery, nutrition, orthodontics, orthopedics, otolaryngology, pediatrics, pediatric dentistry, physical anthropology, plastic surgery, prosthodontics, psychiatry, psychology, social work, and speech-language pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary care provider should refer every child whom they suspect has an abnormal head shape to a craniofacial team. The expertise of a plastic surgeon with craniofacial training and experience should be sought if an interdisciplinary team is not available in the local community. Clinical expertise in diagnosis and treatment is maintained by a large volume of patients. Immediate referral to a craniofacial team for evaluation and imaging at a specialized children's hospital saves time and increases the efficiency of resource utilization. Patients should be evaluated as soon as possible, preferably within the first few weeks after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/54\">",
"     54",
"    </a>",
"    ]. However, referral is appropriate at any age.",
"   </p>",
"   <p>",
"    Imaging need not be performed before referral. Plain radiographs and CTs performed by inexperienced personnel may be substandard and need to be repeated. Three-dimensional CT reconstructions are not typically performed at centers without a craniofacial team; if they are performed at such centers, they may not be reformatted correctly.",
"   </p>",
"   <p>",
"    The craniofacial team develops and implements the treatment plan and provides coordination of care, which should be provided at the local level whenever possible. The team monitors short- and long-term outcomes, including the satisfaction and psychosocial well-being of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/55-57\">",
"     55-57",
"    </a>",
"    ], as well as effects on growth, function, and appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/58\">",
"     58",
"    </a>",
"    ]. Efforts are made to assist the families of craniofacial patients in adjusting to the demands and stress placed upon them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical repair of craniosynostosis is performed to prevent intracranial hypertension and improve socialization by normalizing the appearance of the face and head [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surgical planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, three-dimensional surface reconstructions using CT is used to plan surgical treatment of complex craniofacial reconstructions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Interactive techniques have been developed that simulate osteotomies and skeletal movements in three dimensions on computer-generated surface images [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The ocular globes are marked to position the orbital segments, and then the osteotomized segments are transposed into normal anatomic relationship with respect to the eyes using animation. The measurements from the computer graphic simulation then are used intraoperatively to establish the correct position of the skeletal segments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred time for surgical intervention is 8 to 12 months of age. At that age, the intracranial volume is sufficiently large, and the child can withstand the stress of surgery. The calvarium is thicker, which allows more stable fixation. In our experience, postoperative regression of cranial position is less likely to occur when surgery is performed at 8 to 12 months than at three to six months of age. However, signs of intracranial hypertension, such as papilledema, a beaten copper appearance on skull radiograph (called &ldquo;copper beaten skull&rdquo;, &ldquo;beaten brass skull&rdquo;, or &ldquo;fingerprinting&rdquo; or &ldquo;thumbprints&rdquo; of the skull) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/66\">",
"     66",
"    </a>",
"    ], or increased ICP measured transcutaneously, require urgent decompression. The different types of craniosynostosis require specific surgical approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Scaphocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scaphocephaly results from premature closure of the sagittal suture. This condition is treated by a strip craniectomy performed at three or four months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/67\">",
"     67",
"    </a>",
"    ]. A limitation of this technique is that reossification and growth arrest can occur prior to completion of remodeling. In children six months to one year of age, a Pi or T craniectomy can be used to improve the cephalic contour. If the deformity is severe, barrel-stave osteotomies with rearrangement of cranial segments is required to achieve the desired contour. Spring-mediated cranioplasty, in which implantable spring expansion devices are used to enhance growth across linear craniectomy, was equally as effective and safe as parietal barrel-stave osteotomies in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Plagiocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior and posterior plagiocephaly result from unilateral coronal and lambdoid synostosis, respectively. Surgical intervention for plagiocephaly is undertaken at 8 to 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/69\">",
"     69",
"    </a>",
"    ]. Bifrontal advancement and cranial remodeling harness the forces of the underlying growing brain to obtain a more natural contour to the frontal region. Resorbable technology has proven invaluable to stabilize the remodeled cranium to minimize growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Trigonocephaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical therapy for trigonocephaly is similar to that used to correct plagiocephaly. However, this approach includes transposition of the lateral orbital rim, expansion of the temporal fossa, and recontouring of the orbital aperture in addition to the bifrontal advancement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Furthermore, the bony interorbital distance is widened by midline release of the area between the eyes with bone wedge grafts, helping to prevent increased intraorbital growth. An alternative method to widen interorbital distance is supraorbital bar step expansion, which does not require a bone graft or metallic miniplate fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, the outcomes of 76 children who underwent surgery for trigonocephaly were assessed at &ge;3 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/73\">",
"     73",
"    </a>",
"    ]. Approximately one-third had abnormal mental development. Factors associated with poor outcome were severe frontal stenosis, cranial reconstruction performed after one year of age, and associated extracranial malformations. Development was strongly influenced by the family environment, but not by the presence of intracranial abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Kleeblattsch&auml;del",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kleeblattsch&auml;del (also known as cloverleaf skull deformity) is caused by the fusion of multiple sutures, which usually results in hydrocephalus. Conventional surgical management advocates shunting prior to definitive craniotomy and bone remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/74\">",
"     74",
"    </a>",
"    ]. Results from a small series suggest that staged cranial vault remodeling with initial ventriculoperitoneal shunting is a better alternative than early remodeling, which is associated with increased risk of pneumonia, meningitis, and excessive bleeding, that result in longer intensive care unit and hospital stays [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3423348\">",
"    <span class=\"h2\">",
"     Surgical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks associated with surgery for craniosynostosis, as with all surgical procedures, include those related to general anesthesia, bleeding, infection, scarring, injury to underlying neurovascular structures, and possible need for additional surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Specific to procedures for craniosynostosis, patients typically require transfusion of at least one unit of packed red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. There also is a risk of injury to underlying orbital or intracranial contents, including the brain and sagittal sinus. Injury to these structures may result in significant neurologic abnormalities, including blindness, weakness, seizures, cerebral edema, coma, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10841/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32281290\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Craniosynostosis is the premature fusion of one or more cranial sutures. The four major sutures are the metopic, coronal, sagittal, and lambdoid, and the three minor sutures are the frontonasal, temporosquamosal, and frontosphenoidal. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Cranial anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premature fusion restricts the growth of the skull perpendicular to the affected suture. Compensatory skull growth occurs parallel to the affected suture in order to accommodate the growing brain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cranial deformation is categorized as scaphocephaly, plagiocephaly, trigonocephaly, or kleeblattsch&auml;del, depending upon which suture(s)",
"      <span class=\"nowrap\">",
"       is/are",
"      </span>",
"      involved. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Categorization of cranial deformities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of craniofacial deformity is primarily based upon physical examination. Radiographic studies, such as plain radiographs and computed tomography (CT), may further characterize the structural abnormality. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several conditions can result in facial asymmetry, including positional flattening (positional plagiocephaly) and congenital torticollis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Differential diagnosis of facial asymmetry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications associated with craniosynostosis include increased intracranial pressure (ICP) and inhibition of brain growth, associated impairments in cognitive and neurodevelopment function, and poor self-esteem and social isolation due to the abnormal appearance. (See",
"      <a class=\"local\" href=\"#H1377304\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The care of patients with craniofacial anomalies requires a multidisciplinary approach. The primary care provider should refer every child whom they suspect has an abnormal head shape to a craniofacial team. The expertise of a plastic surgeon with craniofacial training and experience should be sought if an interdisciplinary team is not available in the local community. Patients should be evaluated as soon as possible, preferably within the first few weeks after birth. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical repair of craniosynostosis is performed to prevent intracranial hypertension and improve socialization by normalizing the appearance of the face and head. Three-dimensional surface reconstructions using CT is used to plan surgical treatment of complex craniofacial reconstructions. The preferred time for surgical intervention is 8 to 12 months of age. The different types of craniosynostosis require specific surgical approaches. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgical approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90472577\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of Samuel Stal, MD. UpToDate wishes to acknowledge his dedicated work on this review and his contributions to its Genetic diseases in children section.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/1\">",
"      Slater BJ, Lenton KA, Kwan MD, et al. Cranial sutures: a brief review. Plast Reconstr Surg 2008; 121:170e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/2\">",
"      Virchow R. Uber den Cretinismus, namentlich in Franken, und uber pathologische Schadelformen. Verhandl Phys-Med Gessellschr Wurzburg, 1851; 2:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/3\">",
"      Shillito J Jr, Matson DD. Craniosynostosis: a review of 519 surgical patients. Pediatrics 1968; 41:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/4\">",
"      Hehr U, Muenke M. Craniosynostosis syndromes: from genes to premature fusion of skull bones. Mol Genet Metab 1999; 68:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/5\">",
"      MOSS ML. The pathogenesis of premature cranial synostosis in man. Acta Anat (Basel) 1959; 37:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/6\">",
"      Fragale A, Tartaglia M, Bernardini S, et al. Decreased proliferation and altered differentiation in osteoblasts from genetically and clinically distinct craniosynostotic disorders. Am J Pathol 1999; 154:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/7\">",
"      Cohen MM Jr. Etiopathogenesis of craniosynostosis. Neurosurg Clin N Am 1991; 2:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/8\">",
"      Johnson D, Wilkie AO. Craniosynostosis. Eur J Hum Genet 2011; 19:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/9\">",
"      Lorenz HP, Hedrick MH, Chang J, et al. The impact of biomolecular medicine and tissue engineering on plastic surgery in the 21st century. Plast Reconstr Surg 2000; 105:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/10\">",
"      Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000; 21:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/11\">",
"      Mulliken JB, Steinberger D, Kunze S, M&uuml;ller U. Molecular diagnosis of bilateral coronal synostosis. Plast Reconstr Surg 1999; 104:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/12\">",
"      Wilkie AO, Byren JC, Hurst JA, et al. Prevalence and complications of single-gene and chromosomal disorders in craniosynostosis. Pediatrics 2010; 126:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/13\">",
"      Fearon JA, McLaughlin EB, Kolar JC. Sagittal craniosynostosis: surgical outcomes and long-term growth. Plast Reconstr Surg 2006; 117:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/14\">",
"      Greenberg BM, Schneider SJ. Trigonocephaly: surgical considerations and long term evaluation. J Craniofac Surg 2006; 17:528.",
"     </a>",
"    </li>",
"    <li>",
"     Marsh JL, Vannier MW. Comprehensive Care for Craniofacial Deformities, Mosby, St. Louis 1985.",
"    </li>",
"    <li>",
"     Gorlin RJ, Pinborg JH, Cohen MM Jr. Syndromes of the head and neck, McGraw-Hill, New York 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/17\">",
"      Cohen MM Jr, MacLean RE. Should syndromes be defined phenotypically or molecularly? Resolution of the dilemma. Am J Med Genet 1999; 86:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/18\">",
"      Bristol RE, Krieger MD, McComb JG. Normally shaped heads with no sutures, normally shaped heads with abnormal sutures, and abnormally shaped heads with normal sutures. J Craniofac Surg 2011; 22:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/19\">",
"      Hoffman WY, McCarthy JG, Cutting CB, Zide BM. Computerized tomographic analysis of orbital hypertelorism repair: spatial relationship of the globe and the bony orbit. Ann Plast Surg 1990; 25:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/20\">",
"      Abramson DL, Janecka IP, Mulliken JB. Abnormalities of the cranial base in synostotic frontal plagiocephaly. J Craniofac Surg 1996; 7:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/21\">",
"      Glat PM, Freund RM, Spector JA, et al. A classification of plagiocephaly utilizing a three-dimensional computer analysis of cranial base landmarks. Ann Plast Surg 1996; 36:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/22\">",
"      Altobelli DE, Kikinis R, Mulliken JB, et al. Computer-assisted three-dimensional planning in craniofacial surgery. Plast Reconstr Surg 1993; 92:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/23\">",
"      Cutting C, Dean D, Bookstein FL, et al. A three-dimensional smooth surface analysis of untreated Crouzon's syndrome in the adult. J Craniofac Surg 1995; 6:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/24\">",
"      Udupa JK, Tian J, Hemmy DC, Tessier P. A Pentium personal computer-based craniofacial three-dimensional imaging and analysis system. J Craniofac Surg 1997; 8:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/25\">",
"      Gault D, Brunelle F, Renier D, Marchac D. The calculation of intracranial volume using CT scans. Childs Nerv Syst 1988; 4:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/26\">",
"      Gault DT, Renier D, Marchac D, et al. Intracranial volume in children with craniosynostosis. J Craniofac Surg 1990; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/27\">",
"      Tartaglia M, Bordoni V, Velardi F, et al. Fibroblast growth factor receptor mutational screening in newborns affected by metopic synostosis. Childs Nerv Syst 1999; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/28\">",
"      Laughlin J, Luerssen TG, Dias MS, Committee on Practice and Ambulatory Medicine, Section on Neurological Surgery. Prevention and management of positional skull deformities in infants. Pediatrics 2011; 128:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/29\">",
"      Turk AE, McCarthy JG, Thorne CH, Wisoff JH. The \"back to sleep campaign\" and deformational plagiocephaly: is there cause for concern? J Craniofac Surg 1996; 7:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/30\">",
"      Hutchison BL, Hutchison LA, Thompson JM, Mitchell EA. Plagiocephaly and brachycephaly in the first two years of life: a prospective cohort study. Pediatrics 2004; 114:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/31\">",
"      Kelly KM, Littlefield TR, Pomatto JK, et al. Importance of early recognition and treatment of deformational plagiocephaly with orthotic cranioplasty. Cleft Palate Craniofac J 1999; 36:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/32\">",
"      Mulliken JB, Vander Woude DL, Hansen M, et al. Analysis of posterior plagiocephaly: deformational versus synostotic. Plast Reconstr Surg 1999; 103:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/33\">",
"      Kadom N, Sze RW. Radiological reasoning: a child with posterior plagiocephaly. AJR Am J Roentgenol 2010; 194:WS5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/34\">",
"      Saeed NR, Wall SA, Dhariwal DK. Management of positional plagiocephaly. Arch Dis Child 2008; 93:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/35\">",
"      Littlefield TR, Beals SP, Manwaring KH, et al. Treatment of craniofacial asymmetry with dynamic orthotic cranioplasty. J Craniofac Surg 1998; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/36\">",
"      Singh A, Wacogne I. What is the role of helmet therapy in positional plagiocephaly? Arch Dis Child 2008; 93:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/37\">",
"      Peitsch WK, Keefer CH, LaBrie RA, Mulliken JB. Incidence of cranial asymmetry in healthy newborns. Pediatrics 2002; 110:e72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/38\">",
"      Hollier L, Kim J, Grayson BH, McCarthy JG. Congenital muscular torticollis and the associated craniofacial changes. Plast Reconstr Surg 2000; 105:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/39\">",
"      Cohen MM Jr. Perspectives on craniofacial asymmetry. III. Common and/or well-known causes of asymmetry. Int J Oral Maxillofac Surg 1995; 24:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/40\">",
"      Mouradian WE. Controversies in the diagnosis and management of craniosynostosis: a panel discussion. Cleft Palate Craniofac J 1998; 35:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/41\">",
"      Czerwinski M, Kolar JC, Fearon JA. Complex craniosynostosis. Plast Reconstr Surg 2011; 128:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/42\">",
"      Tamburrini G, Caldarelli M, Massimi L, et al. Intracranial pressure monitoring in children with single suture and complex craniosynostosis: a review. Childs Nerv Syst 2005; 21:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/43\">",
"      Eide PK, Helseth E, Due-T&oslash;nnessen B, Lundar T. Assessment of continuous intracranial pressure recordings in childhood craniosynostosis. Pediatr Neurosurg 2002; 37:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/44\">",
"      Fok H, Jones BM, Gault DG, et al. Relationship between intracranial pressure and intracranial volume in craniosynostosis. Br J Plast Surg 1992; 45:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/45\">",
"      Gault DT, Renier D, Marchac D, Jones BM. Intracranial pressure and intracranial volume in children with craniosynostosis. Plast Reconstr Surg 1992; 90:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/46\">",
"      Becker DB, Petersen JD, Kane AA, et al. Speech, cognitive, and behavioral outcomes in nonsyndromic craniosynostosis. Plast Reconstr Surg 2005; 116:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/47\">",
"      Speltz ML, Kapp-Simon KA, Cunningham M, et al. Single-suture craniosynostosis: a review of neurobehavioral research and theory. J Pediatr Psychol 2004; 29:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/48\">",
"      Kapp-Simon KA, Speltz ML, Cunningham ML, et al. Neurodevelopment of children with single suture craniosynostosis: a review. Childs Nerv Syst 2007; 23:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/49\">",
"      Starr JR, Collett BR, Gaither R, et al. Multicenter study of neurodevelopment in 3-year-old children with and without single-suture craniosynostosis. Arch Pediatr Adolesc Med 2012; 166:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/50\">",
"      Chieffo D, Tamburrini G, Massimi L, et al. Long-term neuropsychological development in single-suture craniosynostosis treated early. J Neurosurg Pediatr 2010; 5:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/51\">",
"      Cohen SR, Cho DC, Nichols SL, et al. American society of maxillofacial surgeons outcome study: preoperative and postoperative neurodevelopmental findings in single-suture craniosynostosis. Plast Reconstr Surg 2004; 114:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/52\">",
"      Parameters for evaluation and treatment of patients with cleft lip/palate or other craniofacial anomalies. American Cleft Palate-Craniofacial Association. March, 1993. Cleft Palate Craniofac J 1993; 30 Suppl:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/53\">",
"      Stal S, Chebret L, McElroy C. The team approach in the management of congenital and acquired deformities. Clin Plast Surg 1998; 25:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/54\">",
"      Ursitti F, Fadda T, Papetti L, et al. Evaluation and management of nonsyndromic craniosynostosis. Acta Paediatr 2011; 100:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/55\">",
"      Lefebvre A, Travis F, Arndt EM, Munro IR. A psychiatric profile before and after reconstructive surgery in children with Apert's syndrome. Br J Plast Surg 1986; 39:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/56\">",
"      Phillips J, Whitaker LA. The social effects of craniofacial deformity and its correction. Cleft Palate J 1979; 16:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/57\">",
"      Lefebvre A, Munro I. The role of psychiatry in a craniofacial team. Plast Reconstr Surg 1978; 61:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/58\">",
"      Stal S, Peterson R, Spira M. Aesthetic considerations and the pediatric population. Clin Plast Surg 1990; 17:133.",
"     </a>",
"    </li>",
"    <li>",
"     Marchac D, Renier D. Craniofacial surgery for craniosynostosis, Little, Brown &amp; Company, Boston 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/60\">",
"      Marchac D, Renier D. Craniofacial surgery for craniosynostosis improves facial growth: a personal case review. Ann Plast Surg 1985; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/61\">",
"      Tessier P, Guiot G, Rougerie J, et al. [Cranio-naso-orbito-facial osteotomies. Hypertelorism]. Ann Chir Plast 1967; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/62\">",
"      Marmulla R, Niederdellmann H. Computer-assisted bone segment navigation. J Craniomaxillofac Surg 1998; 26:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/63\">",
"      Marmulla R, Niederdellmann H. Surgical planning of computer-assisted repositioning osteotomies. Plast Reconstr Surg 1999; 104:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/64\">",
"      Emmez H, K&uuml;&ccedil;&uuml;k&ouml;d&uuml;k I, B&ouml;rcek AO, et al. Effectiveness of skull models and surgical simulation: comparison of outcome between different surgical techniques in patients with isolated brachycephaly. Childs Nerv Syst 2009; 25:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/65\">",
"      Gate&ntilde;o J, Teichgraeber JF, Aguilar E. Computer planning for distraction osteogenesis. Plast Reconstr Surg 2000; 105:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/66\">",
"      Agrawal D, Steinbok P, Cochrane DD. Significance of beaten copper appearance on skull radiographs in children with isolated sagittal synostosis. Childs Nerv Syst 2007; 23:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/67\">",
"      Shah MN, Kane AA, Petersen JD, et al. Endoscopically assisted versus open repair of sagittal craniosynostosis: the St. Louis Children's Hospital experience. J Neurosurg Pediatr 2011; 8:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/68\">",
"      Taylor JA, Maugans TA. Comparison of spring-mediated cranioplasty to minimally invasive strip craniectomy and barrel staving for early treatment of sagittal craniosynostosis. J Craniofac Surg 2011; 22:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/69\">",
"      Adamo MA, Pollack IF. Current management of craniosynostosis. Neurosurgery Quarterly. 2009; 19:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/70\">",
"      Havlik RJ, Azurin DJ, Bartlett SP, Whitaker LA. Analysis and treatment of severe trigonocephaly. Plast Reconstr Surg 1999; 103:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/71\">",
"      McCarthy JG, Bradley JP, Longaker MT. Step expansion of the frontal bar: correction of trigonocephaly. J Craniofac Surg 1996; 7:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/72\">",
"      Kelleher MO, Murray DJ, McGillivary A, et al. Non-syndromic trigonocephaly: surgical decision making and long-term cosmetic results. Childs Nerv Syst 2007; 23:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/73\">",
"      Bottero L, Lajeunie E, Arnaud E, et al. Functional outcome after surgery for trigonocephaly. Plast Reconstr Surg 1998; 102:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/74\">",
"      Goh KY, Ahuja A, Fok TF, Poon WS. Cloverleaf skull--when should one operate? Singapore Med J 1997; 38:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/75\">",
"      Jarrahy R, Kawamoto HK, Keagle J, et al. Three tenets for staged correction of Kleeblattsch&auml;del or cloverleaf skull deformity. Plast Reconstr Surg 2009; 123:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/76\">",
"      Ghali GE, Sinn DP, Tantipasawasin S. Management of nonsyndromic craniosynostosis. Atlas Oral Maxillofac Surg Clin North Am 2002; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/77\">",
"      Teichgraeber JF, Ault JK, Baumgartner J, et al. Deformational posterior plagiocephaly: diagnosis and treatment. Cleft Palate Craniofac J 2002; 39:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10841/abstract/78\">",
"      Foster KA, Frim DM, McKinnon M. Recurrence of synostosis following surgical repair of craniosynostosis. Plast Reconstr Surg 2008; 121:70e.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2910 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10841=[""].join("\n");
var outline_f10_37_10841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32281290\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRANIAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CATEGORIZATION OF CRANIAL DEFORMITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Scaphocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Plagiocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Trigonocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Kleeblattsch&auml;del",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acrocephaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other deformities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cephalometrics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIFFERENTIAL DIAGNOSIS OF FACIAL ASYMMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Positional flattening (positional plagiocephaly)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Congenital torticollis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1378999\">",
"      Other causes of facial asymmetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1377304\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1377311\">",
"      Increased ICP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1377318\">",
"      Development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SURGICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surgical planning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Scaphocephaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Plagiocephaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Trigonocephaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Kleeblattsch&auml;del",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3423348\">",
"      Surgical complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32281290\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90472577\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2910|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/32/16898\" title=\"figure 1\">",
"      Fontanelles and suture lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/51/1854\" title=\"figure 2\">",
"      Skull growth and development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/49/39699\" title=\"figure 3\">",
"      Synostosis variations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/63/30719\" title=\"figure 4\">",
"      Plagiocephaly comparison",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2910|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/51/37683\" title=\"picture 1\">",
"      Scaphocephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2910|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/23/1403\" title=\"table 1\">",
"      Age of fontanelle closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/15/6395\" title=\"table 2\">",
"      Age of suture closure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=related_link\">",
"      Congenital muscular torticollis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=related_link\">",
"      Craniosynostosis syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20169?source=related_link\">",
"      Etiology, prenatal diagnosis, obstetrical management, and recurrence of orofacial clefts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44581?source=related_link\">",
"      Facial clefts and holoprosencephaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_37_10842="Treatment of atopic dermatitis (eczema)";
var content_f10_37_10842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of atopic dermatitis (eczema)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10842/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10842/contributors\">",
"     William L Weston, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10842/contributors\">",
"     William Howe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10842/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10842/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10842/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/37/10842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/37/10842/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/37/10842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis (AD) is a chronic inflammatory skin condition that appears to involve a genetic defect in the proteins supporting the epidermal barrier. Atopy, referring to \"out of place\", describes a group of disorders that include eczema, asthma, and allergic rhinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/1\">",
"     1",
"    </a>",
"    ]. However, such a link between AD and asthma and hay fever has been called into question and is now controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=see_link&amp;anchor=H8#H8\">",
"     \"Risk factors for asthma\", section on 'Atopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The terms \"dermatitis\" and \"eczema\" are frequently used interchangeably. When the term \"eczema\" is used alone, it usually refers to atopic dermatitis (atopic eczema). \"Eczematous\" also connotes some scaling, crusting, or serous oozing as opposed to mere erythema.",
"   </p>",
"   <p>",
"    Conventional therapy for atopic dermatitis is reviewed here. The management of severe, refractory atopic dermatitis and the epidemiology, pathogenesis, clinical manifestations, and diagnosis of atopic dermatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link\">",
"     \"Management of severe refractory atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in the therapy of atopic dermatitis have focused on epidermal barrier repair as genetic studies have demonstrated epidermal filaggrin mutations as a likely cause of AD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/2-4,7\">",
"     2-4,7",
"    </a>",
"    ]. Epidermal filaggrin mutations result in dry and sensitive skin. Currently, standard modalities will continue to be important in the long-term management of these patients, centering around the use of topical antiinflammatory preparations and lubrication of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Most cases of atopic dermatitis are chronic. Thus, the goal of therapy is to improve symptoms while minimizing exposure to potentially toxic drugs.",
"   </p>",
"   <p>",
"    One systematic review of randomized, controlled trials of therapies for atopic dermatitis found that there was reasonable evidence from these studies to support the use of topical corticosteroids, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , ultraviolet light therapy, and some psychological approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/10\">",
"     10",
"    </a>",
"    ]. For other modalities there was either insufficient or absent evidence to support their use. Subsequent to that review, there have been a number of randomized trials published demonstrating the effectiveness of topical calcineurin inhibitors. While the absence of evidence does not imply absence of efficacy, there is a need for well designed studies in the therapy of atopic dermatitis.",
"   </p>",
"   <p>",
"    The general approach to treatment involves the elimination of exacerbating factors, restoring the skin's abnormal barrier function, and hydrating the skin. We recommend the use of emollients in patients with noninflamed skin, and the use of either topical corticosteroids or topical calcineurin inhibitors in patients with inflamed skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ELIMINATION OF EXACERBATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exacerbating factors in atopic dermatitis that disrupt an abnormal epidermal barrier include excessive bathing, low humidity environments, emotional stress, xerosis (dry skin), overheating of skin, and exposure to solvents and detergents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Avoiding these situations is helpful for acute flares as well as for long-term management. Since atopic individuals tend to respond more readily to pruritic stimuli, anything that tends to induce itch in an individual should be avoided.",
"   </p>",
"   <p>",
"    Adjunctive measures that can be helpful in all patients with dermatitis include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid trigger factors such as heat, perspiration, low humidity",
"     </li>",
"     <li>",
"      Treat skin infections such as staphylococcus aureus and herpes simplex (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Management of infection'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Use antihistamines for sedation and control of itching (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Controlling pruritus'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Treat stress and anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is controversy regarding whether environmental or food allergies are an exacerbating factor in a small subset of patients with atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAINTAINING SKIN HYDRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaporation of water on the skin leads to xerosis in patients with atopic dermatitis; skin hydration is a key component of their overall management. Lotions, which have a high water and low oil content, can worsen xerosis via evaporation and trigger a flare of the disease. In contrast, thick creams (eg, Eucerin",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Cetaphil",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Nutraderm",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), which have a low water content, or ointments (eg, petroleum jelly, Vaseline",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Aquaphor",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), which have zero water content, better protect against xerosis, but some patients may complain that they are greasy.",
"   </p>",
"   <p>",
"    There are a number of topical \"therapeutic moisturizers\" available in the US by prescription. These agents contain a variety of components intended to improve skin barrier function and are expensive. There is little data demonstrating their efficacy, but a randomized trial suggests that they are no more effective than over-the-counter emollients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/14\">",
"     14",
"    </a>",
"    ]. They are discussed separately. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/3/41010?source=see_link\">",
"     \"Emollients: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial in infants with AD who required moderate or high potency topical steroids found that infants treated with emollients had significantly decreased requirements for topical steroids compared with a control group of infants who were not treated with emollients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/15\">",
"     15",
"    </a>",
"    ]. Emollients are best applied immediately after bathing when the skin is well hydrated.",
"   </p>",
"   <p>",
"    Some controversy exists concerning whether showering or bathing is preferable in patients with atopic dermatitis. Most authorities recommend a hydrating bath followed by immediate emollient application, but others recommend a shower of short duration. Emollients are the key to restoring the defective epidermal barrier. No well designed studies have been published to address this controversy. We feel that either option is reasonable but suggest bathing to most patients; whether bath or shower, rapid application of emollients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prescribed topical preparations is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONTROLLING PRURITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines are widely used as a therapeutic adjunct in patients with atopic dermatitis to treat both pruritus and eye irritation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/16\">",
"     16",
"    </a>",
"    ]. The evidence supporting their use is relatively weak since no large, randomized, placebo-controlled trials with definitive conclusions have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/17\">",
"     17",
"    </a>",
"    ]. Nevertheless, the sedating antihistamines appear to be most effective (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    ) although their major benefit is likely to be sedation. Nonsedating preparations such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    may occasionally also be useful, especially when there is an urticarial component. Doses higher than normal may be necessary.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     Doxepin",
"    </a>",
"    , a tricyclic antidepressant with potent H1 and H2 blocking properties, is valuable as a second-line antihistamine if others fail. Tepid baths to hydrate and cool the skin can also temporarily relieve itching.",
"   </p>",
"   <p>",
"    Wet dressings (wet wraps) help soothe the skin, reduce pruritus, reduce redness, debride crusts, and limit access to the skin. Emollients are applied to the skin, and dampened cotton garments are worn over the affected area and covered with a dry garment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/18\">",
"     18",
"    </a>",
"    ]. The patient may use these dressings overnight or change them every eight hours during the day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THERAPIES FOR INFLAMMATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topically applied corticosteroids are the mainstay of therapy for AD. A low potency corticosteroid cream or ointment (eg, 1 or 2.5%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) is effective for patients with mild atopic dermatitis (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). A medium potency corticosteroid ointment (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    0.025% or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    0.1%) may be needed for those with more severe disease. Higher potency topical corticosteroids can be used for up to 10 days in some patients with acute flares, and then replaced with lower potency preparations until the lesions resolve.",
"   </p>",
"   <p>",
"    Topical corticosteroids can be used one or more times daily, although no clear benefit has been demonstrated with more than once daily application [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. Additional emollients may not be required if the corticosteroid is prescribed in an ointment base.",
"   </p>",
"   <p>",
"    Potent steroids (class I-IV) (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) are generally avoided in skin folds and on the face; however, limited brief use of potent steroids may produce a rapid response after which patients can be switched to lower potency preparations. In general, the use of potent steroids in these areas should be limited to care prescribed by a dermatologist.",
"   </p>",
"   <p>",
"    In adolescents and adults, an acute exacerbation of chronic atopic dermatitis can sometimes be aborted by a short course of systemic glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three to four days, then 20 to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three to four days). This strategy is not recommended for infants and young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance therapy that includes intermittent use of a topical corticosteroid may help prevent relapse. (See",
"    <a class=\"local\" href=\"#H41442152\">",
"     'Prevention of relapses'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical calcineurin inhibitors appear to be effective for the treatment of atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/23\">",
"     23",
"    </a>",
"    ], and, unlike topical corticosteroids, do not cause skin atrophy or other glucocorticoid adverse effects. For this reason they may be particularly useful on the face, neck, and in skin folds. Both topical preparations are approved by the US Food and Drug Administration (FDA) for use in children over the age of two. However, concerns have been raised by the FDA about a possible link to cancers.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (ointment) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    (cream) are applied twice a day. Tacrolimus comes in two strengths; the 0.1% formulation is appropriate initial therapy for adults, and the 0.03% formulation is appropriate for children and for adults who do not tolerate the higher dose. In patients who do not tolerate tacrolimus because of burning or stinging, pimecrolimus may be better tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy and minor side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical calcineurin inhibitors are generally recognized as being equal in strength to low potency (Class IV) topical steroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ), and should be considered a second-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is an effective second-line alternative to topical corticosteroids [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/25-29\">",
"       25-29",
"      </a>",
"      ]. In addition to its inhibitory effect on cytokine production, topical tacrolimus causes alterations in epidermal antigen-presenting dendritic cells that may result in decreased immunologic response to antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/30\">",
"       30",
"      </a>",
"      ]. The efficacy of tacrolimus has been demonstrated in several randomized, controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/25,31-33\">",
"       25,31-33",
"      </a>",
"      ]. Unlike topical corticosteroids, tacrolimus ointment does not cause skin atrophy, which may provide an advantage for patients with facial disease. Tacrolimus has been used successfully in patients with refractory eyelid disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/34\">",
"       34",
"      </a>",
"      ]. Transient burning, erythema, and pruritus are the most common adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       Pimecrolimus",
"      </a>",
"      1% cream is a calcineurin inhibitor like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      that was developed specifically to treat inflammatory skin conditions. Its mechanism of action is similar to topical tacrolimus, and it does not appear to have systemic immune effects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/35\">",
"       35",
"      </a>",
"      ]. A pooled analysis of two independent, six-week trials that included 403 children with predominantly moderate atopic dermatitis found significant benefits with pimecrolimus therapy compared with vehicle treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/36\">",
"       36",
"      </a>",
"      ]. A randomized trial of early treatment with pimecrolimus in 713 children found that pimecrolimus was effective in preventing flares of atopic dermatitis and reduced the need for topical steroids; benefits persisted after one year of use [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/37\">",
"       37",
"      </a>",
"      ]. Another randomized trial of 543 adults with atopic dermatitis also found that pimecrolimus 1% cream applied twice daily at the first sign of disease activity significantly reduced the number of flares over a 26 week period [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10940755\">",
"    <span class=\"h3\">",
"     Comparison studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    ointment, particularly the 0.1% preparation, may be somewhat more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    cream, although it may also cause somewhat greater local irritation. Examples of studies supporting this concept include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A six-week randomized trial sponsored by the manufacturer of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      that compared twice daily treatment with pimecrolimus 1% cream with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      0.03% ointment in 141 children (ages 2 to 17) with moderate atopic dermatitis concluded that pimecrolimus had better local tolerability [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/39\">",
"       39",
"      </a>",
"      ]. Although the authors reported no difference in efficacy between the treatments, after six weeks there appeared to be a trend toward more children having almost or completely cleared atopic dermatitis when treated with tacrolimus (42 versus 30 percent, p = 0.12).",
"     </li>",
"     <li>",
"      A report of three six-week randomized trials sponsored by the manufacturer of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      found similar results [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/40\">",
"       40",
"      </a>",
"      ]. The trials, which enrolled a total of 1065 patients, compared twice daily treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      1% cream with tacrolimus ointment (0.03% in 426 children with mild atopic dermatitis; 0.1% in 226 children with moderate to severe atopic dermatitis and in 413 adults with mild to very severe atopic dermatitis). In a combined analysis, significantly more patients treated with tacrolimus had almost or completely cleared atopic dermatitis (43 versus 31 percent). More adults treated with tacrolimus noted burning at the application site, typically early in the course of therapy. In pediatric patients with mild disease (who were treated with the lower concentration of tacrolimus used in the study above), there was a nonsignificant trend toward greater clearing with tacrolimus (57 versus 50 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systematic reviews of randomized trials have suggested that topical calcineurin inhibitors and low potency topical steroids have similar efficacy when used to treat moderate to severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In a subsequent randomized, non-inferiority trial of children with moderate to severe atopic dermatitis who had failed to improve sufficiently with topical corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.03% ointment applied twice daily for three weeks was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    0.005% ointment (a high potency topical corticosteroid) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/41\">",
"     41",
"    </a>",
"    ]. Of note, 60 percent of the patients in this study had previously been treated with a high potency or superpotent topical corticosteroid, a factor that may have induced bias favoring tacrolimus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although in controlled trials the topical calcineurin inhibitors have appeared to be safe in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/25,31,32,42,43\">",
"     25,31,32,42,43",
"    </a>",
"    ], in 2005, based upon case reports, animal studies, and the known risks with systemic calcineurin inhibitors, the FDA issued warnings about a possible link between the topical calcineurin inhibitors and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/44\">",
"     44",
"    </a>",
"    ], and in 2006 placed a \"black box\" warning on the prescribing information for these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues of concern include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal studies in mice, rats, and monkeys have found an increased risk of lymphoma and skin cancers with topical or oral exposure to calcineurin inhibitors. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      As of December 2004, the FDA had received 29 reports of cancers in adults and children treated with topical calcineurin inhibitors; approximately half the cases were lymphomas and the other half were cutaneous tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, no definite causal relationship has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/46\">",
"     46",
"    </a>",
"    ], and two case-control studies did not detect an increased risk of lymphoma among patients treated with topical calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. While further study is underway, the FDA has made the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use these agents only as second-line therapy in patients unresponsive to or intolerant of other treatments",
"     </li>",
"     <li>",
"      Avoid the use of these agents in children younger than two years of age; clinical studies have found higher rates of upper respiratory infections in children younger than two who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"     </li>",
"     <li>",
"      Use these agents only for short periods of time and use the minimum amount necessary to control symptoms; avoid continuous use",
"     </li>",
"     <li>",
"      Avoid the use of these agents in patients with compromised immune systems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of better data, these seem like reasonable precautions. However, providers and patients will need to weigh the risks and benefits in comparison to those of other therapies. In particular, calcineurin inhibitors may continue to have an important role in the management of atopic dermatitis in areas at high risk for skin atrophy when treated with corticosteroids (eg, face) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41442152\">",
"    <span class=\"h1\">",
"     PREVENTION OF RELAPSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest proactive therapy to prevent relapse in adolescents and adults with moderate to severe (",
"    <a class=\"graphic graphic_picture graphicRef64525 graphicRef55375 \" href=\"UTD.htm?31/48/32520\">",
"     picture 1A-B",
"    </a>",
"    ) atopic dermatitis that responds to continuous therapy with topical corticosteroids or calcineurin inhibitors (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Therapies for inflammation'",
"    </a>",
"    above). After induction of remission, we suggest intermittent therapy with moderate to high potency topical corticosteroids (group three to five) (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). The steroid should be applied once daily to previously affected skin areas for two consecutive days per week (ie, weekends) and may be continued for up to 16 weeks. Flares of atopic dermatitis that occur during intermittent treatment may be treated by resuming continuous use of topical corticosteroids or calcineurin inhibitors that have been effective for the patient in the past. Similar strategies for proactive therapy are recommended in 2012 European and American guidelines for the management of atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants and young children with moderate to severe atopic dermatitis (",
"    <a class=\"graphic graphic_picture graphicRef77457 graphicRef57650 \" href=\"UTD.htm?24/12/24772\">",
"     picture 2A-B",
"    </a>",
"    ) who have frequent flares, proactive intermittent therapy with low potency (groups six and seven) topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) may be beneficial in preventing relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/52\">",
"     52",
"    </a>",
"    ]. The steroid should be applied once daily to previously affected skin areas for two consecutive days per week (ie, weekends) and may be continued for up to 16 weeks. Flares of atopic dermatitis that occur during intermittent treatment may be treated by resuming continuous use of topical corticosteroids that have been effective for the patient in the past.",
"   </p>",
"   <p>",
"    In meta-analyses of randomized trials, proactive, intermittent therapy with moderate to high potency corticosteroids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , after achieving disease control with continuous use of these agents, was effective in reducing the risk of subsequent flares [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/53\">",
"     53",
"    </a>",
"    ]. However, there were fewer adverse effects with corticosteroids, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of four randomized trials, topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate (once daily for two consecutive days per week for 16 weeks) reduced the risk of a subsequent flare by 54 percent (RR 0.46, 95% CI 0.38&ndash;0.55) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/53\">",
"       53",
"      </a>",
"      ]. No serious adverse events were reported.",
"     </li>",
"     <li>",
"      In a meta-analysis of three randomized trials, topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (once daily two to three days per week for 10 to 12 months) reduced the risk of a subsequent flare by 22 percent (RR 0.78, 95% CI 0.60&ndash;0.78) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/53\">",
"       53",
"      </a>",
"      ]. Adverse effects included pruritus, burning sensation, skin infections, and bronchopneumonia. In addition, four patients developed a cancer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of severe atopic dermatitis that is resistant to conventional therapy is a challenge and frequently requires the help of a dermatologist. A number of alternatives are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultraviolet light therapy (phototherapy) with PUVA (psoralens plus ultraviolet A radiation), broadband UVA, broadband UVB, combined UVA and UVB, narrow-band UVB, or UVA1 is successful in controlling atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. Some studies suggest that either narrowband UVB or UVA-1 may be more effective than treatment with combined UVA and UVB, broadband UVA, or broadband UVB [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/54,55,57-59\">",
"       54,55,57-59",
"      </a>",
"      ]. However, phototherapy is expensive ($25 to $100 per treatment) and prolonged treatment may lead to an increased risk of melanoma and nonmelanoma skin cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. Thus, treatment with this modality is limited to severe cases.",
"     </li>",
"     <li>",
"      Oral calcineurin inhibitors can be used to treat atopic dermatitis. Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , in doses of 3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, is effective for severe atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/63\">",
"       63",
"      </a>",
"      ]. In one study that used a body weight-independent dosing of cyclosporine microemulsion, 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      was effective when compared to 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in the short term treatment of atopic dermatitis, and was associated with better renal tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/64\">",
"       64",
"      </a>",
"      ]. Short courses of cyclosporine 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (multiple courses of 12 weeks) also have been successful in children with atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/65\">",
"       65",
"      </a>",
"      ]. Monitoring of patients receiving cyclosporine includes measuring blood pressure and serum creatinine every two weeks for three months, followed by monthly monitoring. Significant elevations of either are an indication to lower the dose or stop treatment. Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      also may be used in some cases, with similar concerns regarding side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/66\">",
"       66",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"      </a>",
"      .) Topical cyclosporine does not appear to be effective [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occasionally immunosuppressants such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/68\">",
"       68",
"      </a>",
"      ], or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil may be used. These therapies should be prescribed by a dermatologist.",
"     </li>",
"     <li>",
"      Patients with pustules should be evaluated with bacterial cultures and treated with appropriate oral antibiotics.",
"     </li>",
"     <li>",
"      Topical preparations containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"       cromolyn sodium",
"      </a>",
"      may provide some benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Probiotic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    and other organisms has been studied for the treatment of atopic dermatitis in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/70\">",
"     70",
"    </a>",
"    ], but is probably not of significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Dietary supplements, including fish oil and vitamins, also do not appear to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The use of Chinese herbal medications for atopic dermatitis has not been adequately evaluated in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8037?source=see_link\">",
"     \"Prebiotics and probiotics for treatment of allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=see_link&amp;anchor=H20#H20\">",
"     \"Chinese herbal medicine for the treatment of allergic diseases\", section on 'Therapy for atopic dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been case reports and small uncontrolled studies showing improvement in refractory cases with the anti-IgE monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/77\">",
"     77",
"    </a>",
"    ] and the anti-CD20 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link&amp;anchor=H24#H24\">",
"     \"Anti-IgE therapy\", section on 'Anti-IgE therapy in other diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atopic dermatitis are at increased risk for cutaneous bacterial, viral, and fungal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus is a frequent skin colonizer in patients with atopic dermatitis. The organism can be isolated from the skin lesions of 76 to 100 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/79\">",
"     79",
"    </a>",
"    ]. S. aureus is isolated from the skin of only 2 to 25 percent of unaffected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/79\">",
"     79",
"    </a>",
"    ]. The increased rates of colonization in patients with atopic dermatitis may be secondary to the impaired epidermal barrier and reduction of cutaneous antimicrobial peptides (cathelicidins and beta-defensins) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of S. aureus colonization may influence the development of atopic dermatitis in young children. A prospective cohort study (n=1079) evaluated the association between nasal colonization with S. aureus and atopic dermatitis in children under the age of two [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/81\">",
"     81",
"    </a>",
"    ]. The presence and severity of atopic dermatitis was assessed via parent questionnaires. Children with positive nasal cultures at the age of six months exhibited a higher prevalence of symptoms of atopic dermatitis during the first and second years of life than those with negative cultures (adjusted OR 1.67, 95% CI 1.15-2.44 and 1.86, 95% CI 1.28-2.69, respectively). S. aureus colonization also had an effect on disease severity. In the second year of life, children who had positive nasal cultures at age 6 months possessed a higher risk for moderate to severe atopic dermatitis (adjusted OR 3.27, 95% CI 1.30-8.03) than for mild disease (adjusted OR 1.57, 95% CI 1.04-2.37). The findings of this survey-based study are not sufficient to implicate S. aureus as a major causative factor of atopic dermatitis; further studies are necessary to determine the role of S. aureus in the development of the clinical features of this disease.",
"   </p>",
"   <p>",
"    Methicillin-resistant S. aureus (MRSA) infections have increased in the general population, and can occur in patients with atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Epidemiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Management of clinical infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with clinically infected skin is recommended. Signs of infection include honey-colored crusting, folliculitis, and pyoderma (",
"    <a class=\"graphic graphic_picture graphicRef74056 graphicRef62234 \" href=\"UTD.htm?32/58/33705\">",
"     picture 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/18\">",
"     18",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    is effective for patients with localized infections, but oral antibiotic therapy with cephalosporins or penicillinase-resistant penicillins are typically used for more extensive infections, depending on local epidemiology [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link&amp;anchor=H11#H11\">",
"     \"Impetigo\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H6#H6\">",
"     \"Cellulitis and erysipelas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend culturing infected skin prior to treatment. If MRSA is present, therapy with an appropriate antibiotic is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\", section on 'Oral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bleach baths",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium hypochlorite 6% solution (liquid chlorine bleach) has activity against S. aureus including MRSA. Dilute bleach baths have been used to decrease the frequency of skin infections in patients with atopic dermatitis, although studies of the effectiveness of this intervention are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Patients are instructed to add one quarter to one half cup of bleach to a full tub (40 gallons) of lukewarm water and then soak in the bath for 5 to 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/18\">",
"     18",
"    </a>",
"    ]. Afterwards, patients rinse with fresh water, pat themselves dry, and immediately apply emollient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prescribed medications. The baths are taken two times per week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Antimicrobials in the absence of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. aureus colonization may be an exacerbating factor for atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/18\">",
"     18",
"    </a>",
"    ]. However, studies conflict on whether antimicrobial therapies for S. aureus colonization are effective in reducing the severity of atopic dermatitis.",
"   </p>",
"   <p>",
"    A systematic review found insufficient evidence to recommend the use of oral antibiotics for the treatment of atopic dermatitis in the absence of clinical infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/84\">",
"     84",
"    </a>",
"    ]. The same review found that topical antibiotics or antiseptics reduced colonization with S. aureus in patients with atopic dermatitis, but could not conclude that treatment with these agents in combination with topical corticosteroids induced greater clinical improvement than topical corticosteroids alone. However, the systematic review primarily was based on poor quality studies, and cannot definitively discount antimicrobial therapies for patients without overt infection.",
"   </p>",
"   <p>",
"    A more recent three month randomized trial (n = 31) of children with atopic dermatitis investigated the effect of antimicrobial therapy on disease severity and found evidence of effectiveness for a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    and bleach baths [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients had acute signs of infection at the start of the trial, but were followed for a total of three months to evaluate the efficacy of bleach baths and mupirocin ointment on disease severity. All patients received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 14 days), but were randomly assigned to receive intranasal mupirocin ointment for five consecutive days per month plus twice weekly bleach baths or intranasal petrolatum and plain water baths.",
"   </p>",
"   <p>",
"    Mean reductions in the Eczema Area and Severity Index (EASI) scores were greater for the treatment group (-10.4 &plusmn; 2.8 after one month and -15.3 &plusmn; 3.8 after three months) versus the control group (-2.5 &plusmn;1.6 after one month and -3.2 &plusmn; 1.6 after three months). The study also assessed EASI scores for areas that were not immersed in the bleach baths (head and neck) versus scores for the rest of the body. In contrast to the submerged body sites, significant reductions in EASI scores were not observed on the head and neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis patients with lesions that are infected with herpes simplex (called eczema herpeticum or Kaposi's varicelliform eruption) should be treated immediately with oral antiviral therapy. Examination reveals skin with punched-out erosions, hemorrhagic crusts,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vesicles (",
"    <a class=\"graphic graphic_picture graphicRef51337 graphicRef74838 graphicRef64142 \" href=\"UTD.htm?17/8/17546\">",
"     picture 4A-C",
"    </a>",
"    ). Involved skin may be pruritic or painful, and lesions may be widespread. The diagnosis should be considered in patients who fail to respond to oral antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/82\">",
"     82",
"    </a>",
"    ]. Cases of life-threatening dissemination have been reported, and intravenous antiviral therapy may be necessary in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with atopic dermatitis may also develop widespread molluscum contagiosum infections (",
"    <a class=\"graphic graphic_picture graphicRef57836 \" href=\"UTD.htm?19/54/20323\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=see_link\">",
"     \"Molluscum contagiosum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatophyte infections are more common in patients with atopic dermatitis, and can be treated with standard regimens of topical or oral antifungals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the Malessezia furfur yeast (a normal component of skin flora) may be an exacerbating factor in patients with",
"    <span class=\"nowrap\">",
"     head/neck",
"    </span>",
"    atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/85\">",
"     85",
"    </a>",
"    ]. Elevated Malassezia-specific IgE levels have been reported in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/37/10842/abstract/85\">",
"     85",
"    </a>",
"    ]. Treatment may result in improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link&amp;anchor=H8#H8\">",
"     \"Role of allergy in atopic dermatitis (eczema)\", section on 'Malassezia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with atopic dermatitis can initially be treated by a nonspecialist. We suggest that patients be referred to a specialist (eg, dermatologist, allergist) in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the diagnosis is uncertain",
"     </li>",
"     <li>",
"      When patients have failed to respond to appropriate therapy",
"     </li>",
"     <li>",
"      If treatment of atopic dermatitis of the face or skin folds with high potency topical corticosteroids is being contemplated",
"     </li>",
"     <li>",
"      If treatment with systemic immunosuppressive agents is being considered",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of atopic dermatitis in pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link&amp;anchor=H24#H24\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Atopic dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=see_link\">",
"       \"Patient information: Eczema (atopic dermatitis) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       \"Patient information: Giving your child over-the-counter medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=see_link\">",
"       \"Patient information: Atopic dermatitis (eczema) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic dermatitis is a chronic inflammatory skin condition that involves a complex interaction between environmental and genetic factors. When the term \"eczema\" is used alone, it usually refers to atopic dermatitis (atopic eczema). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The goals of treatment are to reduce symptoms (pruritus and dermatitis), prevent exacerbations, and minimize therapeutic risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive measures that can be helpful in all patients with dermatitis include (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Elimination of exacerbating factors'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid trigger factors such as heat, perspiration, low humidity",
"     </li>",
"     <li>",
"      Treat skin infections such as staphylococcus aureus and herpes simplex",
"     </li>",
"     <li>",
"      Use antihistamines for sedation and control of itching",
"     </li>",
"     <li>",
"      Treat stress and anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sleeping environment with minimal dust and upholstery reduces exposure to house dust mites and may potentially reduce the severity of atopic dermatitis.",
"   </p>",
"   <p>",
"    In infants, avoidance of certain foods can be helpful. Common food triggers include eggs, nuts, peanut butter, chocolate, milk, seafoods, and soya.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Noninflamed skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;When skin is not inflamed, patients should bathe daily and then immediately apply an emollient. Patients should use the highest oil content emollient that they will accept. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Maintaining skin hydration'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Inflamed skin",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with inflamed skin be initially treated with topical therapy using corticosteroids rather than a calcineurin inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Topical corticosteroids can be applied once daily. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The face and skin folds are areas that are at high risk for atrophy with corticosteroids. Initial therapy in these areas should start with a low potency steroid (class V or VI) (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      ), such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13828?source=see_link\">",
"       desonide",
"      </a>",
"      0.05% ointment daily for up to three weeks. Potent steroids (class I-IV) are generally avoided in skin folds and on the face; however, limited brief use of potent steroids may produce a rapid response after which patients can be switched to lower potency preparations. In general, the use of potent steroids in these areas should be limited to care prescribed by a dermatologist. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who require therapy to the face or skin folds for more than three weeks be treated with a topical calcineurin inhibitor (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      ) rather than a topical steroid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Topical calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      are applied twice a day. Tacrolimus comes in two strengths; the 0.1% formulation is appropriate initial therapy for adults, and the 0.03% formulation is appropriate for children and for adults who do not tolerate the higher dose. In patients who do not tolerate tacrolimus because of burning or stinging, pimecrolimus may be better tolerated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Topical calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      may be used on any skin surface. However, these agents are expensive, and there have been concerns raised about reports of malignancies in children and adults. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest proactive therapy to prevent relapse in adolescents and adults with moderate to severe (",
"      <a class=\"graphic graphic_picture graphicRef64525 graphicRef55375 \" href=\"UTD.htm?31/48/32520\">",
"       picture 1A-B",
"      </a>",
"      ) atopic dermatitis that responds to continuous therapy with topical corticosteroids or calcineurin inhibitors (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ).We suggest medium to high potency topical corticosteroids (groups three to five) (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      ) rather than topical calcineurin inhibitors for proactive intermittent therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The steroid is applied once daily for two consecutive days per week for up to 16 weeks. (See",
"      <a class=\"local\" href=\"#H41442152\">",
"       'Prevention of relapses'",
"      </a>",
"      above.) If patients fail topical treatment, systemic immunosuppressive therapy may be of benefit. Such therapy should generally be prescribed by a specialist and is generally avoided in children. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with refractory disease with recurrent skin infections may need evaluation for immune deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link&amp;anchor=H13#H13\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Infected skin",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcus aureus infections should be treated with topical or oral antibiotics. When skin infection is suspected, a culture should be obtained to rule out methicillin-resistant S. aureus (MRSA). Although colonization with S. aureus appears to be an exacerbating factor for atopic dermatitis, further studies are necessary to determine whether antimicrobial interventions that reduce S. aureus colonization reduce disease severity. Bleach baths may be used adjunctively to reduce skin colonization. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Bleach baths'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Herpes simplex infections (eczema herpeticum or Kaposi's varicelliform eruption) in atopic dermatitis can be widespread, and rarely life-threatening. Affected patients should be treated with oral antivirals. Intravenous therapy may be necessary in severe cases. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Viral infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/1\">",
"      Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112:S118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/2\">",
"      Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol 2007; 127:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/3\">",
"      Chan LS. Atopic dermatitis in 2008. Curr Dir Autoimmun 2008; 10:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/4\">",
"      McGrath JA, Uitto J. The filaggrin story: novel insights into skin-barrier function and disease. Trends Mol Med 2008; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/5\">",
"      Brenninkmeijer EE, Schram ME, Leeflang MM, et al. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol 2008; 158:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/6\">",
"      Baurecht H, Irvine AD, Novak N, et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007; 120:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/7\">",
"      Rogers AJ, Celed&oacute;n JC, Lasky-Su JA, et al. Filaggrin mutations confer susceptibility to atopic dermatitis but not to asthma. J Allergy Clin Immunol 2007; 120:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/8\">",
"      Charman C. Clinical evidence: atopic eczema. BMJ 1999; 318:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/9\">",
"      Sudilovsky A, Muir JG, Bocobo FC. A comparison of single and multiple applications of halcinonide cream. Int J Dermatol 1981; 20:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/10\">",
"      Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/11\">",
"      Langan SM, Williams HC. What causes worsening of eczema? A systematic review. Br J Dermatol 2006; 155:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/12\">",
"      Langan SM, Bourke JF, Silcocks P, Williams HC. An exploratory prospective observational study of environmental factors exacerbating atopic eczema in children. Br J Dermatol 2006; 154:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/13\">",
"      Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003; 148 Suppl 63:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/14\">",
"      Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011; 10:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/15\">",
"      Grimalt R, Mengeaud V, Cambazard F, Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007; 214:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/16\">",
"      Nuovo J, Ellsworth AJ, Larson EB. Treatment of atopic dermatitis with antihistamines: lessons from a single-patient, randomized clinical trial. J Am Board Fam Pract 1992; 5:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/17\">",
"      Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/18\">",
"      Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics 2008; 122:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/19\">",
"      Jones SM, Sampson HA. The role of allergens in atopic dermatitis. Clin Rev Allergy 1993; 11:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/20\">",
"      Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/21\">",
"      Koopmans B, Lasthein Andersen B, Mork NJ, et al. Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily. J Dermatol Treat 1995; 6:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/22\">",
"      Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005; 152:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/23\">",
"      Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005; 330:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/24\">",
"      Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig 2006; 26:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/25\">",
"      Aoyama H, Tabata N, Tanaka M, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995; 133:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/26\">",
"      Ruzicka T, Bieber T, Sch&ouml;pf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/27\">",
"      Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol 2001; 107:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/28\">",
"      Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/29\">",
"      Fonacier L, Spergel J, Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/30\">",
"      Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/31\">",
"      Reitamo S, Wollenberg A, Sch&ouml;pf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/32\">",
"      Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/33\">",
"      Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/34\">",
"      Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/35\">",
"      Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005; 52:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/36\">",
"      Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/37\">",
"      Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110:e2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/38\">",
"      Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 2008; 158:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/39\">",
"      Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/40\">",
"      Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/41\">",
"      Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol 2010; 21:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/42\">",
"      Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/43\">",
"      Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109:539.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Public Health Advisory for Elidel and Protopic (3/10/2005) file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153956.htm (Accessed on September 21, 2011).",
"    </li>",
"    <li>",
"     Public Health Advisory for Elidel and Protopic (3/10/2005) file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153956.htm (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/46\">",
"      Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/47\">",
"      Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/48\">",
"      Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/49\">",
"      Ring J, M&ouml;hrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008; 31:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/50\">",
"      Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/51\">",
"      Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/52\">",
"      Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/53\">",
"      Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/54\">",
"      Jekler J, Lark&ouml; O. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study. J Am Acad Dermatol 1990; 22:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/55\">",
"      Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/56\">",
"      Grundmann-Kollmann M, Behrens S, Podda M, et al. Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol 1999; 40:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/57\">",
"      Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/58\">",
"      Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed 2007; 23:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/59\">",
"      Gambichler T, Othlinghaus N, Tomi NS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/60\">",
"      Stern RS, Nichols KT, V&auml;kev&auml; LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/61\">",
"      Stern RS, Laird N, Melski J, et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/62\">",
"      Lindel&ouml;f B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/63\">",
"      de Prost Y. Atopic dermatitis: recent therapeutic advances. Pediatr Dermatol 1992; 9:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/64\">",
"      Czech W, Br&auml;utigam M, Weidinger G, Sch&ouml;pf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/65\">",
"      Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/66\">",
"      Wolff K, Fleming C, Hanifin J, et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005; 152:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/67\">",
"      De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991; 71:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/68\">",
"      Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/69\">",
"      Stainer R, Matthews S, Arshad SH, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. Br J Dermatol 2005; 152:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/70\">",
"      Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/71\">",
"      Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008; 121:e850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/72\">",
"      Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2008; :CD006135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/73\">",
"      van der Aa LB, Heymans HS, van Aalderen WM, Sprikkelman AB. Probiotics and prebiotics in atopic dermatitis: review of the theoretical background and clinical evidence. Pediatr Allergy Immunol 2010; 21:e355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/74\">",
"      van Gool CJ, Zeegers MP, Thijs C. Oral essential fatty acid supplementation in atopic dermatitis-a meta-analysis of placebo-controlled trials. Br J Dermatol 2004; 150:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/75\">",
"      Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev 2012; 2:CD005205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/76\">",
"      Zhang W, Leonard T, Bath-Hextall F, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev 2005; :CD002291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/77\">",
"      Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/78\">",
"      Simon D, H&ouml;sli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/79\">",
"      Huang JT, Abrams M, Tlougan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009; 123:e808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/80\">",
"      Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/81\">",
"      Lebon A, Labout JA, Verbrugh HA, et al. Role of Staphylococcus aureus nasal colonization in atopic dermatitis in infants: the Generation R Study. Arch Pediatr Adolesc Med 2009; 163:745.",
"     </a>",
"    </li>",
"    <li>",
"     Leung DY, Eichenfield LF, Boguniewicz M. Atopic dermatitis (atopic eczema). In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff K, Goldsmith LA, Katz SI, et al (Eds), McGraw-Hill, 2008. p.146.",
"    </li>",
"    <li>",
"     Metry D, Browning J, Rousseau, et al. Sodium hypochlorite (bleach) baths: a potential measure to reduce the incidence of recurrent, cutaneous staphylococcus aureus superinfection among susceptible populations. Poster presented at the Society for Pediatric Dermatology annual meeting, Chicago, IL, July 12-15, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/84\">",
"      Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008; :CD003871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/37/10842/abstract/85\">",
"      Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol 2009; 60:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1730 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10842=[""].join("\n");
var outline_f10_37_10842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ELIMINATION OF EXACERBATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAINTAINING SKIN HYDRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONTROLLING PRURITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THERAPIES FOR INFLAMMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy and minor side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10940755\">",
"      - Comparison studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41442152\">",
"      PREVENTION OF RELAPSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Management of clinical infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bleach baths",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Antimicrobials in the absence of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Noninflamed skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Inflamed skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Infected skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/1730\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1730|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/31/24051\" title=\"picture 1A\">",
"      Adult atopic dermatitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/10/42147\" title=\"picture 1B\">",
"      Adult atopic dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/55/23408\" title=\"picture 2A\">",
"      Atopic dermatitis infantile I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/4/28751\" title=\"picture 2B\">",
"      Flex atopic dermatitis PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/35/29236\" title=\"picture 3A\">",
"      Infected eczema hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/9/4246\" title=\"picture 3B\">",
"      Infected eczema ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/22/39268\" title=\"picture 4A\">",
"      Eczema herpeticum arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/29/7634\" title=\"picture 4B\">",
"      Eczema herpeticum hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/0/19459\" title=\"picture 4C\">",
"      Eczema herpeticum face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/54/20323\" title=\"picture 5\">",
"      Molluscum and eczema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1730|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31496?source=related_link\">",
"      Chinese herbal medicine for the treatment of allergic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/3/41010?source=related_link\">",
"      Emollients: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=related_link\">",
"      Management of severe refractory atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/23/15730?source=related_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=related_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8037?source=related_link\">",
"      Prebiotics and probiotics for treatment of allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=related_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20682?source=related_link\">",
"      Risk factors for asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_37_10843="Fibromyalgia v myofascial pain";
var content_f10_37_10843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of fibromyalgia versus myofascial pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fibromyalgia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Myofascial pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td>",
"        Generalized",
"       </td>",
"       <td>",
"        Localized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examination",
"       </td>",
"       <td>",
"        Tender points",
"       </td>",
"       <td>",
"        Trigger points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"       <td>",
"        Prominent",
"       </td>",
"       <td>",
"        Data unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gender",
"       </td>",
"       <td>",
"        90 percent female",
"       </td>",
"       <td>",
"        Data unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Course",
"       </td>",
"       <td>",
"        Chronic",
"       </td>",
"       <td>",
"        May be self-limited",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10843=[""].join("\n");
var outline_f10_37_10843=null;
var title_f10_37_10844="Irradiation blood indications";
var content_f10_37_10844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indication for irradiation of cellular blood components for the prevention of transfusion-associated graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Currently accepted indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunocompromised hematopoietic stem cell&nbsp;recipients&nbsp;or organ transplant recipients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with hematologic disorders who will be undergoing marrow transplantation imminently",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrauterine transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal exchange transfusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature, low birthweight neonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Congenital cell-mediated immunodeficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thymic hypoplasia (DiGeorge syndrome), Wiskott-Aldrich syndrome, Leiner's disease, 5' nucleotidase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic lymphocytic leukemia (CLL) patients or other patients receiving fludarabine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recipients of directed donations from biologic relatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recipients of donation from HLA-matched donors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recipients who are heterozygous at an HLA locus for which the donor is homozygous and shares an allele; most common in genetically homogeneous populations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Probably indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematologic malignancies other than Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solid tumors treated with cytotoxic agents",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <ol>",
"      <li>",
"       Przepiorka D, et al. Am J Clin Pathol 1996; 106:6 and Webb IJ, et al. Transfusion-associated graft-vs-host disease. In: Transfusion reactions, 3rd ed, Popovsky MA (Ed), American Association of Blood Banks Press, Bethesda 2007. p.237.",
"      </li>",
"      <li>",
"       AABB Technical Manual, 17th ed, Roback JD, Grossman BJ, Harris T, et al, (Eds). American Association of Blood Banks Press, Bethesda 2011. p.755.&nbsp;&nbsp;&nbsp;",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10844=[""].join("\n");
var outline_f10_37_10844=null;
var title_f10_37_10845="PROSTQA probabilities of erection after radical prostatectomy";
var content_f10_37_10845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PROSTQA model-predicted probabilities of men having functional erections suitable for intercourse two years after radical prostatectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Planned surgical technique",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Patient age, y",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Pretreatment PSA level, ng/mL",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Predicted functional erections after treatment, percent (95% CI) (by pretreatment sexual HRQOL score)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        67",
"       </td>",
"       <td class=\"subtitle2\">",
"        83",
"       </td>",
"       <td class=\"subtitle2\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Nerve-sparing",
"       </td>",
"       <td rowspan=\"2\">",
"        50",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        35 (25-45)",
"       </td>",
"       <td>",
"        52 (43-61)",
"       </td>",
"       <td>",
"        70 (61-77)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        18 (9-34)",
"       </td>",
"       <td>",
"        32 (18-49)",
"       </td>",
"       <td>",
"        50 (32-68)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        60",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        23 (18-30)",
"       </td>",
"       <td>",
"        38 (33-44)",
"       </td>",
"       <td>",
"        57 (49-64)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        11 (0-21)",
"       </td>",
"       <td>",
"        21 (12-34)",
"       </td>",
"       <td>",
"        36 (22-53)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        70",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        15 (10-22)",
"       </td>",
"       <td>",
"        26 (19-35)",
"       </td>",
"       <td>",
"        43 (32-55)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        7 (3-14)",
"       </td>",
"       <td>",
"        13 (7-24)",
"       </td>",
"       <td>",
"        24 (13-41)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Non&ndash;nerve-sparing",
"       </td>",
"       <td rowspan=\"2\">",
"        50",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        13 (5-30)",
"       </td>",
"       <td>",
"        23 (9-46)",
"       </td>",
"       <td>",
"        39 (18-64)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        6 (2-18)",
"       </td>",
"       <td>",
"        11 (4-31)",
"       </td>",
"       <td>",
"        21 (7-48)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        60",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        8 (3-19)",
"       </td>",
"       <td>",
"        14 (6-32)",
"       </td>",
"       <td>",
"        27 (12-50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        3 (1-11)",
"       </td>",
"       <td>",
"        7 (2-19)",
"       </td>",
"       <td>",
"        13 (4-34)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        70",
"       </td>",
"       <td>",
"        &le;10",
"       </td>",
"       <td>",
"        5 (2-12)",
"       </td>",
"       <td>",
"        9 (3-22)",
"       </td>",
"       <td>",
"        17 (7-37)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        2 (1-7)",
"       </td>",
"       <td>",
"        4 (1-12)",
"       </td>",
"       <td>",
"        8 (3-23)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PROSTQA: Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; PSA: prostate-specific antigen; HRQOL: health-related quality of life.",
"     <br>",
"      * Specific values of pretreatment sexual functioning (Expanded Prostate Cancer Index Composite scores of 67, 83, and 100; range of 0-100, with a higher score representing better function) are tabulated to represent cohort distribution (25th, 50th, and 75th percentiles of scores among prostatectomy-treated patients) as well as to reflect a clinically relevant set of possible pretreatment sexual functioning. Across all treatment groups, these percentiles correspond to 358 patients (36 percent) with pretreatment sexual HRQOL scores of 67 or less, 441 (45 percent) with scores of 68-99, and 186 (19 percent) with scores of 100.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205. Copyright &copy; 2011 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10845=[""].join("\n");
var outline_f10_37_10845=null;
var title_f10_37_10846="Meta-analysis of ACAS and ACST";
var content_f10_37_10846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80838&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Meta-analysis of ACAS and ACST",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of endarterectomy for asymptomatic carotid stenosis on the risk of any stroke and operative death by sex in the ACST and ACAS trials.",
"    <div class=\"footnotes\">",
"     CI: confidence interval; OR: odds ratio.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid stenosis: asymptomatic carotid surgery trial. Stroke 2004; 35:2425. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10846=[""].join("\n");
var outline_f10_37_10846=null;
var title_f10_37_10847="Circuvent device for delivery of MDI or nebulized medication";
var content_f10_37_10847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Circuvent&reg; device for delivery of MDI or nebulized medication during mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CircuVent",
"    <sup>",
"     &reg;",
"    </sup>",
"    device allows delivery of aerosolized medications (MDI or nebulized) to mechanically ventilated patients without removing the heat and moisture exchanger (HME). Using a valve system, air bypasses the HME during delivery of the aerosol.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Smiths Medical. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_37_10847=[""].join("\n");
var outline_f10_37_10847=null;
